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https://doi.org/10.1016/j.celrep.2021.109958SUMMARYImpaired hepatic glucose and lipidmetabolism are hallmarks of type 2 diabetes. Increased sulfide production
or sulfidedonor compoundsmaybeneficially regulatehepaticmetabolism.Disposal of sulfide through the sul-
fide oxidation pathway (SOP) is critical for maintaining sulfide within a safe physiological range.We show that
mice lacking the liver- enriched mitochondrial SOP enzyme thiosulfate sulfurtransferase (Tst/mice) exhibit
high circulating sulfide, increased gluconeogenesis, hypertriglyceridemia, and fatty liver. Unexpectedly,
hepatic sulfide levels are normal in Tst/ mice because of exaggerated induction of sulfide disposal, with
associated suppression of global protein persulfidation and nuclear respiratory factor 2 target protein levels.
Hepatic proteomic andpersulfidomic profiles convergeongluconeogenesis and lipidmetabolism, revealing a
selective deficit in medium-chain fatty acid oxidation in Tst/mice. We reveal a critical role of TST in hepatic
metabolism that has implications for sulfide donor strategies in the context of metabolic disease.INTRODUCTION
The prevalence of type 2 diabetes (T2D) continues to soar in par-
allel with that of obesity (World Health Organization, 2016).
Increased hepatic glucose production and aberrant hepatic lipidC
This is an open access article undmetabolism are cardinal features of T2D (Consoli et al., 1989;
Lewis et al., 2002). Dysregulation of hepatic nutrient metabolism
in T2D is a promising area for therapeutic intervention because it
precipitates the more severe liver pathologies that manifest
along the spectrum of non-alcoholic fatty liver disease (NAFLD),ell Reports 37, 109958, November 9, 2021 ª 2021 The Authors. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESSsteatosis, steatohepatitis, and hepatocellular carcinoma (Caron
et al., 2011).
Hydrogen sulfide (hereafter referred to as sulfide), an endoge-
nously produced gaseous signaling molecule (Abe and Kimura,
1996; Wang, 2012; Mishanina et al., 2015; Filipovic et al., 2017),
has recently emerged as amodulator of nutrientmetabolism (De-
sai et al., 2011; Szabo, 2011;Hine et al., 2015; Carter andMorton,
2016). Enzymatic sulfide production from sulfur amino acids is
catalyzed by cystathionine beta synthase (CBS), cystathionine
gamma lyase (CTH) (Chen et al., 2004; Singh et al., 2009), and
3-mercaptopyruvate sulfurtransferase (MPST) (Shibuya et al.,
2009; Mikami et al., 2011; Yadav et al., 2013). Thioredoxin-medi-
ated reduction of cysteine persulfides on proteins also regulates
free sulfide and cysteine persulfide levels (Wedmann et al., 2016).
Endogenously produced and exogenously administered sulfide
specifically influences hepatic glucose and lipid metabolism
(Mani et al., 2014; Pichette and Gagnon, 2016). Thus, in vitro,
treatment of murine hepatocytes with sodium hydrosulfide
(NaHS), or overexpression of rat Cth in HepG2 liver cells
increased glucose production through increased gluconeogen-
esis and reduced glycogen storage (Zhang et al., 2013).
Conversely, glucose production was lower in hepatocytes from
Cth gene knockout (Cth/) mice, which exhibit low sulfide pro-
duction (Zhang et al., 2013). Elevation of sulfide with NaHS
administration in vivo reduced cholesterol and triglyceride accu-
mulation in the liver of high-fat diet (HFD)-fed mice (Wu et al.,
2015). In contrast, inter-crossing of sulfide production-deficient
Cth/ mice with the hyperlipidemic Apoe/ mouse strain
(Cth/Apoe/) produced a phenotype of elevated plasma
cholesterol following exposure to an atherogenic diet (Mani
et al., 2013). Consistent with their higher cholesterol, Cth/
Apoe/ mice developed fatty streak lesions earlier than
Apoe/mice, and this effect was reversed by NaHS administra-
tion (Mani et al., 2013). Sulfide may also indirectly affect hepatic
nutrient metabolism through its effect on hepatic artery vasore-
laxation and, thus, liver perfusion (Fiorucci et al., 2005; Distrutti
et al., 2008). The apparently beneficial effects of sulfide adminis-
tration in multiple disease indications has led to a major drive to-
ward development of targeted H2S donor molecules as a thera-
peutic approach (Whiteman et al., 2011; Sestito et al., 2017).
However, an often overlooked aspect of net sulfide exposure,
key to the efficacyof therapeuticH2Sdonors, is that it is regulated
through its oxidative disposal. Thus, endogenous sulfide expo-
sure is actively limited to prevent mitochondrial respiratory
toxicity (Reiffenstein, 1992; Tiranti et al., 2009; Libiad et al.,
2018). Sulfide is oxidized rapidly (Hildebrandt and Grieshaber,
2008; Norris et al., 2011) through themitochondrial sulfide oxida-
tionpathway (SOP), consisting of sulfidequinoneoxidoreductase
(SQOR), persulfide dioxygenase (ETHE1/PDO), and thiosulfate
sulfurtransferase (TST; also known as rhodanese) (Hildebrandt
and Grieshaber, 2008; Jackson et al., 2012; Libiad et al., 2014).
The liver is highly abundant in SOP enzymes and is amajor organ
of whole-body sulfide disposal (Norris et al., 2011). Mice lacking
the Ethe1 gene (Ethe1/) die of fatal sulfide toxicity (Tiranti et al.,
2009), consistent with its critical role in sulfide oxidation and the
severe pathological consequences of unchecked sulfide buildup
in tissues. However, the importance of mitochondrial TST in the
SOP in vivo remains obscure. In contrast to Ethe1/ mice,2 Cell Reports 37, 109958, November 9, 2021Tst/ mice were grossly normal despite exhibiting substantially
elevated blood sulfide levels, as implied by qualitative measures
(Morton et al., 2016). This revealed an important but distinct role
of TST in the SOP in vivo. Nevertheless, Tst/ mice showed an
apparently diabetogenic impairment of glucose tolerance (Mor-
ton et al., 2016), consistent with the concept that increased sul-
fide promotes hepatic glucose production (Zhang et al., 2013).
Because Tst deficiency is a model of chronic but viable sulfide
elevation, determining the molecular mechanisms driving the
aberrant metabolic profile can provide important insights into
the optimal range for therapeutic sulfide exposure, particularly
in light of the current interest in developing mitochondrially tar-
geted sulfide donors (Ger}o et al., 2016; Karwi et al., 2018). To
this end, we sought to define the effect of Tst deficiency on the
underlying molecular pathways that affect hepatic metabolism.
RESULTS
Tst/ mice exhibit increased hepatic gluconeogenesis
and dyslipidemia despite mild peripheral insulin
sensitization
TST mRNA expression is highest in the liver (http://biogps.org/
#goto=genereport&id=22117; tissue hierarchy of expression
was validated in our own mouse substrain; Figure S1A). We
therefore hypothesized that liver TST deficiency was the prin-
cipal driver of the impaired glucose tolerance observed previ-
ously in Tst/ mice (Morton et al., 2016). Tst/ mice exhibited
higher glucose levels than C57BL/6J controls in response to
pyruvate challenge, consistent with higher hepatic glucose pro-
duction (Figure 1A). We next tested phosphoenolpyruvate car-
boxykinase (PEPCK) activity, a key enzyme of de novo hepatic
glucose synthesis, and found that it was higher in liver homoge-
nates from Tst/ mice (Figure 1B). Next we performed a 1-h
13C3-pyruvate metabolite pulse incorporation experiment in iso-
lated hepatocytes cultured in 12C3-pyruvate-freemedium. Hepa-
tocytes from Tst/ mice displayed 13C labeling consistent with
increased metabolism of pyruvate to oxaloacetate, a critical
early step in gluconeogenesis. Specifically, aspartate, which is
derived from pyruvate via oxaloacetate, was increased signifi-
cantly in Tst/ hepatocytes (Figure 1C). A trend toward higher
13C3 malate and lower
13C2 acetyl-coenzyme A (CoA) was also
observed (Figures S1B and S1C). 13C3 lactate was similar be-
tween genotypes, suggesting a similar activity of glycolytic
disposal of pyruvate through lactate dehydrogenase (Figures
S1B and S1C). Isotopologue distribution is shown in Figure S1C.
Total pool sizes for all measured metabolites were similar be-
tween genotypes (Figure S1D). Although not a direct measure
of glucose production, the data from in vitro hepatocytes sug-
gested skewing of hepatocytemetabolism toward gluconeogen-
esis, and we therefore investigated this possibility. Indeed,
consistent with increased endogenous glucose production in
Tst/ mice, fasting plasma glucose was higher in Tst/ mice
relative to 6Jmice during the pre-clamp 3-3H glucose tracer infu-
sion phase (60–90min after the tracer) of euglycemic, hyperinsu-
linemic (EH) clamp experiments (Figure 1D; Table S1A). Higher
plasma glucose levels in Tst/ mice under these conditions
was not explained by lower glucose utilization in Tst/ mice;




Figure 1. Tst deletion results in impaired
glucose and lipid metabolism
(A) Plasma glucose over 120 min, following pyruvate
(i.p., 1.5 mg/g) administration in overnight-fasted
C57BL/6J (black line, n = 9) and Tst/ (red line, n = 8)
ND-fed mice.
(B) Extinction of NADH, measured by absorbance at
340 nm, coupled to PEPCK activity from liver ho-
mogenates taken from C57BL/6J (white bar, n = 6)
and Tst—/— (red bar, n = 6) ND-fed mice.
(C) Production of 13C (M+3) aspartate generated after
a 1-h pulse of 1 mM 3-carbon labeled 13C (M+3) py-
ruvate in 12C pyruvate-free medium, expressed as a
percentage of the total amount of detected metabo-
lite, in primary hepatocytes from C57BL/6J (white
bars, n = 6) and Tst/ (red bars, n = 5) ND-fed mice.
(D) Blood glucose during the pre-clamp phase of the
EHclamp fromC57BL/6J (black lines) and Tst/ (red
lines) mice fed a control (ND, solid lines, n = 3, 6) or
high-fat diet (HFD, broken lines, n = 6, 7).
(E) Mean integrated radioactive glucose (inversely
related to whole-body glucose uptake) during a EH
clamp from ND-fed C57BL/6J control (white, n = 3)
and Tst/ (red, n = 6) mice.
(F) Plasma glucose, expressed as percent of baseline
glucose, over 120 min following insulin (i.p., 1 mU/g)
administration in 4-h-fastedC57BL/6J (black line, n =
8) and Tst/ (red line, n = 7) ND-fed mice.
(G) HPLC-quantified total and VLDL plasma triglyc-
eride in 4-h-fasted C57BL/6J (white bar, n = 6) and
Tst/ (red bar, n = 6) ND-fed mice.
(H) Representative light microscopy images of liver
sections stained with oil red O from normal diet (ND)-
fed or HFD-fed C57BL/6J and Tst/ mice. Magnifi-
cation is 40X.
(I) Analysis of the area of red staining (oil red O) after thresholding, using ImageJ, from ND-fed (no pattern, n = 3–4/genotype) or HFD-fed (hatched pattern, n = 4–5/
genotype) C57BL/6J (white bars) and Tst/ (red bars) mice.
Data are represented asmean± SEM. Significancewas calculated using repeated-measures ANOVA (A and F), 2-way ANOVA (I), 3-way repeated-measures ANOVA
(D), or unpaired two-tailedStudent’s t test (B,C, E, andG); *p< 0.05, **p < 0.01, ***p<0.001, ****p <0.0001. For (D), significant effects of time (****), diet (*) and genotype
(*) were found. For (F), the analysis was performed on absolute glucose values and demonstrated a significant effect of time (****) and an interaction between time and
genotype (*). t tests revealed that the decrement of glucose frombaseline 30 and 60min after insulin was greater in Tst/mice (*). For (I), nomain genotype effectwas
found, but a significant effect of diet (***) and an interaction (*) were found. Post hoc analysis using Sidak’s multiple comparison test shows an effect of diet on the 6J
controls (***), whereas no effect of diet is found on Tst/ mice. See also Figures S1 and S2 and Table S1.
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derived parameter used to infer glucose production, was also
comparable between genotypes (Table S1A). However, deriva-
tion of glucose turnover requires that glucose levels are stable
during the period in which it is calculated. In our pre-clamp base-
line period, a highly significant effect of time (Figure 1D) indicated
that this assumption was not met; thus, true endogenous
glucose production cannot be inferred from the glucose turnover
parameter in this instance. Combined with the pyruvate toler-
ance, PEPCK activity, and 13C3-pyruvate pulse data, higher fast-
ing glucose levels in Tst/ mice, given comparable glucose
utilization, are most likely due to higher endogenous glucose
production.
We next wished to explore whether the changes to glucose
metabolism were driven by insulin resistance. Liver glycogen, a
marker of long-term carbohydrate storage typically impaired
with insulin resistance, was comparable between Tst/ and
C57BL/6J control mice (Figure S2A). Despite unchanged
steady-state markers of hepatic insulin sensitivity, impairedglucose tolerance, described previously in Tst/ mice (Morton
et al., 2016), suggested that whole-body, and usually hepatic, in-
sulin resistance was present. We investigated this using the eu-
glycemic clamp, where, unexpectedly, we observedwhole-body
insulin sensitization under these short-term steady-state condi-
tions. During the clamp, when insulin was high and blood
glucose levels were maintained constant, the glucose infusion
rate was comparable between genotypes (Table S1B). However,
an increase in whole-body glucose uptake (integral glucose) by
tissues in Tst/ mice was apparent (Figure 1E; Table S1B), sup-
porting increased peripheral insulin sensitivity, with a direction-
ally consistent trend for increased glucose uptake into several
tissues. We confirmed this finding using standard insulin toler-
ance tests, where the glucose decrement in response to insulin
was greater in Tst/ mice (Figure 1F; Figure S2B). These data
demonstrate a net increase in dynamicwhole-body insulin sensi-
tivity despite increased hepatic glucose output in Tst/ mice.
Finally, we assessed whole-body glucose homeostasis with
the EH clamp method after chronic HFD feeding. Under theseCell Reports 37, 109958, November 9, 2021 3
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Figure 2. Tst deletion results in increased he-
patic sulfur excretion and a reduction of pro-
tein persulfidation
(A) Schematic showing mammalian metabolism of
hydrogen sulfide. The canonical production en-
zymes are shown in the cytosol. MPST, mercapto-
pyruvate sulfurtransferase; CBS, cystathionine beta
synthase; CTH, cystathionine gamma lyase. Mito-
chondrial oxidation and disposal of hydrogen sulfide
occurs through the SOP through the actions of
SQOR (sulfide quinone oxidoreductase), ETHE1
(PDO), TST (thiosulfate sulfurtransferase), and SUOX
(sulfite oxidase). These seven enzymes are major
contributors to intracellular sulfide (and other inor-
ganic sulfur) metabolism. For simplicity, the diagram
does not include sulfide production, which can
occur within mitochondria, or disposal pathways in
the cytosol. The identity of oxidized sulfur species
produced by SQOR remain disputed. The precise
role of TST and other enzymes shown here remains
under investigation.
(B) Cysteine concentrations (MBB-HPLC) in medium incubated with primary hepatocytes in the presence (hatched pattern) or absence (no pattern) of 1 mM
methionine from C57BL/6J (white bars, n = 4/treatment) and Tst/ (red bars, n = 4/treatment) mice.
(C) GSH concentrations (MBB-HPLC) in medium incubated with primary hepatocytes in the presence (hatched pattern) or absence (no pattern) of 1 mM
methionine from C57BL/6J (white bars, n = 4/treatment) and Tst/ (red bars, n = 4/treatment) mice.
(D) Pie chart depicting the proportion of liver peptides that are significantly higher (82 peptides, purple space) or lower (311 peptides, yellow space) in their
persulfidation rate in Tst/ (n = 3) relative to C57BL/6J (n = 3) mice.
(E) Total DTT-released cysteine-persulfidated liver protein as measured by REVERT total protein stain following western blotting, normalized to the total input
protein of the sample from Tst/ (red bar, n = 4) and C57BL/6J (white bar, n = 4) mice.
Data with error bars are represented as mean ± SEM. Significance was calculated using 2-way ANOVA (B and C) or Student’s t test (E); *p < 0.05, **p < 0.01. For
(B) and (C), the 2-way ANOVA reveals a main effect of genotype, indicated by * or ** on the histogram. A significant effect of methionine was also found for (B) and
(C), not indicated on the histogram. For (D), peptides were selected as being significant at a P-diff of 0.95 or greater. See also Figure S3 and Table S2.
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output (Figure 1D) but showed convergence of the insulin sensi-
tivity profile with that of insulin-resistant C57BL/6J mice.
We also assessed whether Tst deficiency was associated with
impaired lipid metabolism, another hallmark of diabetes. Fast
protein liquid chromatography analysis of triglyceride levels
and their lipoprotein distribution revealed significantly higher
total plasma triglycerides in Tst/ mice (Figure 1G). The higher
triglyceride was selectively associated with an increased very
low density lipoprotein (VLDL) triglyceride fraction (Figure 1G),
consistent with a dominant liver-driven impairment in lipid meta-
bolism (Mason, 1998). Total and distinct lipoprotein fraction
plasma cholesterol levels were similar between genotypes (Fig-
ures S2C and S2D), suggestive of a triglyceride-selective effect
of Tst deficiency on hepatic lipid efflux. HFD feeding significantly
increased the liver lipid content of C57BL/6J mice but did not
further increase the elevated lipid levels in the liver of Tst/
mice (Figures 1H and 1I).
TST deficiency elicits compensatory hepatic sulfide
disposal mechanisms that drive reduced global protein
persulfidation
A role of TST in disposal of sulfide has been suggested by its
participation in the SOP (Hildebrandt and Grieshaber, 2008;
Libiad et al., 2014) and supported in vivo by the qualitatively
higher blood sulfide of Tst/ mice (Morton et al., 2016), shown
schematically in Figure 2A. Here we quantified circulating sul-
fide, showing an approximately 10-fold elevation in the blood
and plasma of Tst/ mice (Table 1). Thiosulfate, an oxidized4 Cell Reports 37, 109958, November 9, 2021metabolite of sulfide (Vitvitsky et al., 2015, 2017) and a TST sub-
strate (Banerjee et al., 2015), was approximately 20-fold higher in
the plasma (Table 1) and profoundly higher (450-fold) in the urine
(Table 1) of Tst/ mice compared with C57BL/6J mice.
Reduced glutathione (rGSH) levels were 2-fold higher in the
plasma of Tst/ mice (Table 1). To determine any direct hepatic
contribution to the elevated systemic sulfide in vivo, whole blood
was sampled from the inferior vena cava (IVC) (Table 1). IVC sul-
fide levels tended to be higher in Tst/ mice, but the magnitude
of the increase (3-fold) did not parallel that in trunk blood (10-
fold), suggesting that the liver was not a major source of the
elevated circulating sulfide. Surprisingly, liver homogenate sul-
fide, thiosulfate, cysteine, and GSH levels were similar between
Tst/ and C57BL/6J mice (Table 1). Further, cultured hepato-
cytes from Tst/ and C57BL/6J mice exhibited similar intracel-
lular sulfide levels, as estimated using P3, a sulfide-selective
fluorescent probe (Singha et al., 2015; Table 1). Mitochondrial
sulfide levels in the liver, reported by MitoA/MitoN (Arndt et al.,
2017), were similarly unchanged between genotypes (Table 1).
The apparently unaltered hepatic steady-state sulfide levels,
despite higher circulating sulfide, suggested that a profound ho-
meostaticmechanismwas invoked in the liver of Tst/mice.We
assessed respiratory sulfide disposal (antimycin sensitive) and
found that this was increased markedly in hepatocytes from
Tst/ mice, whereas antimycin-insensitive sulfide disposal
was relatively reduced compared with hepatocytes from
C57BL/6J mice (Table S2). Isolated liver mitochondria from
Tst/ hepatocytes also exhibited a higher sulfide disposal rate
(Table S2). In addition, cysteine andGSHwere excreted at higher
Table 1. Sulfur species in blood, urine, tissue, and cells
C57BL/6J Tst/ Tst//6J ratio Significance
Trunk blood (micromolar)a
MBB-S (sulfide) 2.28 ± 0.43 22.18 ± 0.85 9.73 ****
MBB-SSO3 (thiosulfate) N/D 6.25 ± 3.17 n.c. ns
Trunk plasma (micromolar)b
MBB-S (sulfide) 1.88 ± 0.64 24.50 ± 2.02 13.03 ****
MBB-SSO3 (thiosulfate) 3.99 ± 0.99 80.29 ± 13.6 20.12 **
MBB-GSH (reduced GSH) 48.0 ± 1.15 86.25 ± 6.27 1.80 ***
Urine (micromoles/creatine/24 h)c
MBB-SSO3 (thiosulfate) 4.99 ± 2.6 2374 ± 319 475.75 ****
IVC (micromolar)d
MBB-S (sulfide) 1.22 ± 0.20 3.58 ± 0.87 2.93 ns (0.08)
MBB-SSO3 (thiosulfate) 6.58 ± 4.51 88.3 ± 13.0 13.42 *
Liver (micromoles/kg wet liver)e
MBB-S (sulfide) 13 ± 1 17 ± 3 1.31 ns
MBB-SSO3 (thiosulfate) 4 ± 1 15 ± 7 3.75 ns
DNFB-GSH (reduced GSH) 6,470 ± 380 6,850 ± 30 1.04 ns
DNFB-cysteine (cysteine) 82 ± 13 67 ± 11 0.82 ns
Sulfide P3 fluorescence (A510 nm/protein)f
Hepatocyte 7.22 ± 1.00 7.89 ± 0.80 1.09 ns
Mitochondrial sulfide (MitoA)g
Liver 0.78 ± 0.16 1.14 ± 0.45 1.46 ns
Tst deletion results in altered sulfur metabolites in blood and liver. Data are represented as mean ± SEM. Significance was calculated using unpaired
two-tailed Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. MMB; monobromobimane.
aSulfide dibimane and thiosulfate-MBB, measured by fluorescence detection following HPLC, from whole blood taken from trunk blood of ND-fed
C57BL/6J (n = 4) and Tst/ (n = 4) mice.
bSulfide dibimane, thiosulfate-MBB, and rGSH-MBB, measured by fluorescence detection following HPLC, from EDTA-plasma of ND-fed C57BL/6J
(n = 4) and Tst/ (n = 4) mice.
cThiosulfate-MBB corrected for creatinine from 24-h urine samples, taken from ND-fed C57Bl6/J (n = 4) and Tst/ (n = 5) mice.
dSulfide dibimane and thiosulfate-MBB fromwhole blood taken from the IVC downstream of the hepatic vein of ND-fed C57BL/6J (n = 3) and Tst/ (n =
3) mice.
eSulfide dibimane, thiosulfate-MBB, rGSH-MBB, and cysteine-MBB from whole liver (n = 4/genotype) of ND-fed C57BL/6J (n = 4) and Tst/ (n = 4)
mice.
fFluorescence from cultured hepatocytes following incubation with P3 (sulfide reactive probe) from ND-fed C57BL/6J (n = 4) and Tst/ (n = 4) mice.
gRatio of MitoN/MitoA from the liver of ND-fed C57BL/6J (n = 5) and Tst/ (n = 5) mice.
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OPEN ACCESSlevels from Tst/ hepatocytes under basal conditions and after
stimulation of sulfur amino acid metabolism by addition of methi-
onine (Figures 2B and 2C). Consistent with higher GSH turnover,
hepatocytes from Tst/ mice showed resistance to exogenous
H2O2-mediated mitochondrial reactive oxygen species (ROS)
production (Figure S3). We next determined the global hepatic
protein persulfidation profile, the major post-translational modi-
fication mediated by sulfide (Krishnan et al., 2011; Kabil et al.,
2014; Koike et al., 2017). Mass spectrometry analysis of malei-
mide-labeled liver peptides revealed a greater abundance of
peptides with a lower persulfidation level (underpersulfidated)
in the liver of Tst/ mice (Figure 2D). We confirmed this using
semiquantitative western blot analysis on pulled down malei-
mide-labeled proteins (Figure 2E). Gene Ontology (GO) analysis
of underpersulfidated peptides (20 GO categories; Table 2)
showed enrichment for ‘‘FAD-binding, methyl transferase,
peroxisome, acyl-CoA dehydrogenase activity, and transami-nase.’’ Overpersulfidated peptides (8 GO categories; Table 2)
were predominantly ‘‘nicotinamide metabolism.’’ Pathway-spe-
cific peptide analysis showed a bias for over-persulfidation in
gluconeogenesis proteins (Figure S4A) and a significantly higher
magnitude of change (independent of direction of change) in per-
sulfidation compared with global persulfidomic changes be-
tween C57BL/6J and Tst/ mice (Figure S4B).
The hepatic proteome of Tst/ mice reveals a distinct
molecular signature of altered sulfur and mitochondrial
nutrient metabolism
To gain molecular insight into the mechanisms underlying the
apparently diabetogenic phenotype in Tst/ mice, we
compared hepatic proteomes of normal diet (ND)-fed mice.
Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis re-
vealed 4 up-regulated pathways in the liver of Tst/mice related
to amino acid metabolism, including sulfur amino acids, andCell Reports 37, 109958, November 9, 2021 5
Table 2. Tst deletion results in differential persulfidation rate of liver proteins
GO ID Name Direction (Tst/ versus 6J) Genes
GO terms identified by log fold change
0050660 FAD binding decreased 12
0008168 methyltransferase activity decreased 9
9
0016741 transferase activity, transferring
one-carbon groups
decreased 9
0008565 protein transporter activity decreased 8
0008238 exopeptidase activity decreased 7
0005777 peroxisome decreased 7
0042579 microbody decreased 7
0003995 acyl-CoA dehydrogenase activity decreased 6
0008483 transaminase activity decreased 6






0016655 oxidoreductase activity, acting on NADH/
NADPH, quinone
decreased 5
0004177 aminopeptidase activity decreased 5
0000059 protein import into nucleus, docking decreased 3
0005643 nuclear pore decreased 3
0031965 nuclear membrane decreased 3
0044453 nuclear membrane part decreased 3
0046930 pore complex decreased 3
0015629 actin cytoskeleton decreased 3
0016652 oxidoreductase activity, NADH/NADPH,
NAD/NADP acceptor
decreased 3







0016651 oxidoreductase activity, NADH/NADPH, increased 5
0003954 NADH dehydrogenase activity increased 4
0008137 NADH dehydrogenase (ubiquinone) activity increased 4
0050136 NADH dehydrogenase (quinone) activity increased 4
0006739 NADP metabolism increased 3
0006769 nicotinamide metabolism increased 3
0006733 oxidoreduction coenzyme metabolism increased 3
Shown are significant GO terms represented by peptides with different persulfidation rates in ND-fed Tst/ mouse liver relative to C57BL/6J mice.
‘‘Direction’’ indicates whether persulfidation is decreased or increased in Tst/ relative to C57BL/6J mice. ‘‘Genes’’ indicates the number of genes
in Tst/ mice that represent the changes driving the GO term.
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OPEN ACCESSsulfur metabolism (Table 3). GO analysis revealed 95 significantly
up-regulated categories in the liver of Tst/ mice (Table S3A).
Among the top categories, 7 referred to amino acid metabolism
and 1 referred to the organellar term ‘‘mitochondrion.’’ KEGG
analysis revealed 27 down-regulated pathways in the liver of
Tst/ mice (Table 3), including phase 1 and 2 detoxification6 Cell Reports 37, 109958, November 9, 2021pathways (cytochrome P450s, GSH, and glucuronidation) and
‘‘lysosome’’ and ‘‘protein processing in the endoplasmic reticu-
lum’’ organellar terms. 213 GO terms were significantly down-
regulated in Tst/mice (Table S4B). Among themost significant
down-regulated terms were phase 2 detoxification ‘‘glutathione
binding,’’ ‘‘glutathione transferase activity,’’ and ‘‘endoplasmic
Table 3. Protein abundance and persulfidation in ND-fed Tst/ liver
Entry Name Genes Significance
KEGG pathways increased in ND Tst/ livera
00250 alanine, aspartate, and glutamate
metabolism
6 ***




04122 sulfur relay system 2 *
KEGG pathways reduced in ND Tst/ liverb
00980 metabolism of xenobiotics by
cytochrome P450
12 ****
00982 drug metabolism – cytochrome P450 12 ****
05204 chemical carcinogenesis 12 ****
00480 glutathione metabolism 8 ***
00040 pentose and glucoronate interconversions 5 **
04142 lysosome 6 **
04390 Hippo signaling pathway 4 **
00500 starch and sucrose metabolism 5 **
05215 prostate cancer 3 **
04024 cAMP signaling pathway 4 *
04141 protein processing in ER 9 *
05211 renal cell carcinoma 3 *
00830 retinol metabolism 6 *
00053 ascorbate and aldarate metabolism 4 *
00860 porphyrin and chlorophyll metabolism 4 *
04722 neurotrophin signaling pathway 3 *
04670 leukocyte transendothelial migration 4 *
04010 MAPK signaling pathway 4 *
04720 long-term potentiation 2 *
04914 progesterone-mediated oocyte maturation 2 *
04062 chemokine signaling pathway 3 *
04110 cell cycle 3 *
04015 Rap1 signaling pathway 4 *
00983 drug metabolism – other enzymes 5 *
04918 thyroid hormone synthesis 3 *
04612 antigen processing and presentation 3 *
05203 viral carcinogenesis 5 *
GO terms common to persulfidome and proteome in ND Tst/ liverc




0008483 transaminase activity decreased increased
0016769 transferase activity, transferring
nitrogenous groups
decreased increased
0003995 acyl-CoA dehydrogenase activity decreased decreased
0005777 peroxisome decreased decreased
0042579 microbody decreased decreased
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
aSignificant KEGG pathway terms represented by proteins that aremore abundant in the liver of ND-fed Tst/ compared with ND-fed C57BL/6Jmice.
bSignificant KEGG pathway terms represented by proteins that are less abundant in the liver of ND-fed Tst/compared with ND-fed C57BL/6J mice.
‘‘Genes’’ indicates the number of genes in Tst/ mice that represent the changes driving the KEGG pathway.
cGO terms that are significantly regulated at the level of cysteine persulfidation and protein abundance in the liver of ND-fed Tst/compared with ND-
fed C57BL/6J mice.






Figure 3. Tst deletion engenders a HFD
feeding-like hepatic proteomewith a distinct
organellar signature
(A) Venn diagram representing the number of pro-
teins significantly different (at p < 0.01) between
ND-fed Tst/ and C57BL/6J mice (red circle) and
the number of regulated proteins between HFD-fed
and ND-fed C57BL/6J (green circle) mice. The
overlap (brown) represents proteins regulated in the
same direction by both comparisons (n = 4/geno-
type).
(B) Number of proteins significantly different (at p <
0.01) between 58%HFDandND in either C57BL/6J
(white bar) or Tst/mice (red bar) (n = 4/genotype).
(C) Pie charts depicting the proportion of individual
liver proteins that are upregulated (blue space)
compared with downregulated (yellow space) after
GO term categorization according to subcellular
location. Top row: ND-fed Tst/ relative to ND-fed
C57BL/6J mice. Bottom row, HFD-fed C57BL/6J
relative to ND-fed C57BL/6J mice. See also Table 3
and Figures S5 and S6.
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rection of change in a representative subset of proteins (Figures
S5A and S5D). The most robust change we observed was
increased MPST protein in whole liver (Figures S5A and S5D)
and mitochondrial subfractions (Figures S5B and S5D). This
change was remarkable because mRNA levels for Mpst were
lower in Tst/mice (Figure S5C), likely as a result of loss of prox-
imalMpst promoter function;Mpst is a paralog of Tst (Nagahara,
2011) juxtaposed approximately 1 kb from the Tst gene. Protein
levels for other sulfide-producing and disposal enzymes were
comparable between genotypes (Table S4). A focused compar-
ison of canonical proteins in glucose and lipid metabolism
pathways (Table S5) revealed four GO categories that were
down-regulated in Tst/ mice: ‘‘lipid metabolic process,’’ ‘‘fatty
acid beta-oxidation,’’ ‘‘acyl-CoA dehydrogenase activity,’’ and
‘‘acyl-CoA hydrolase activity’’ (Table S5). Canonical insulin-regu-
lated proteins were largely comparable between genotypes (Ta-
ble S6).
Hepatic protein expression in Tst/ mice is consistent
with lower NRF2 activation
We performed a transcription factor binding site (TFBS) enrich-
ment analysis in thepromoters of proteins thatwere up-regulated
in the liver of Tst/ mice to look for potential hub transcriptional
drivers of the proteome profile (Figure S6A). This revealed a sta-
tistically significant under-representation of TFBS for the sulfide-
responsive (Yang et al., 2013; Xie et al., 2016) NRF2 transcription
factor (Figure S6A). Consistent with reduced hepatic NRF2 acti-
vation, 10 of 47 known NRF2-regulated proteins were lower in
the liver of ND-fed Tst/ mice compared with C57BL/6J mice
(Figure S6B).
The proteome of TST deficiency versus HFD response in
C57BL/6J mice reveals distinct regulation of lipid
metabolism, sulfide metabolism, and detoxification
pathways
We examined mechanistic commonalities between the diabeto-
genic hepatic phenotype of Tst/ mice and that induced by the8 Cell Reports 37, 109958, November 9, 2021diabetogenic HFD feeding regimen in C57BL/6J mice. ND-fed
Tst/ mice were in a pre-existing diabetogenic state (Figure 1)
that does not worsen with HFD feeding (Figures 1H and 1I; Table
S1), suggesting gross phenotypic convergence of the two geno-
types after HFD feeding. We compared the identity and direction
of change of the 188 proteins differentially expressed in ND-fed
Tst/ mice (versus ND-fed C57BL/6J mice; Figure 3A) with pro-
teins that were differentially expressed in response to HFD
feeding in C57BL/6J mice (432 proteins; Figure 3A). There was
a striking 67% overlap in individual proteins (126) in this compar-
ison (Figure 3A). When we analyzed these two protein signatures
for directionally shared pathways, one upregulated KEGG
pathway, ‘‘glycine, serine and threonine metabolism’’ (Table
S7A), and 12 downregulated KEGG pathways, including ‘‘drug
metabolism’’ and ‘‘endoplasmic reticulum’’ (Table S8B), were
common to the liver of ND-fed Tst/ and HFD-fed C57BL/6J
mice. Consistent with a pre-existing HFD-like proteome, the dy-
namic response to HFD in the liver of Tst/ mice was muted
relative to that observed in C57BL6J mice (106 proteins, a 4-
fold lower response; Figure 3B). Focusing on the sulfide
pathway, MPST and sulfite oxidase (SUOX) were increased by
HFD feeding in C57BL/6J and Tst/ mice (Table S8). The
HFD-induced increase in MPST was less pronounced in the liver
of Tst/ mice, likely reflecting that it is already elevated in ND-
fed Tst/ mice. We then considered contrasting rather than
congruent proteomics responses arising from TST deficiency
versus HFD responses in C57BL/6J mice to illuminate potential
novel pathways underlying the otherwise functionally similar dia-
betogenic hepatic Tst/ phenotype. 5 KEGG pathways (Table
S9A) and 4 GO terms (Table S9B) were regulated oppositely in
this comparison. Strikingly, the GO terms were all related to lipid
metabolism, which was up-regulated in the HFD response but
down-regulated with TST deficiency (Tables S9A and S9B). An
organelle-focused protein analysis showed shared upregulation
of mitochondrial and endoplasmic reticulum pathways between
TST deficiency (Figure 3C, top row) and C57BL/6J HFD re-
sponses (Figure 3C, bottom row) but a striking discordance in




Figure 4. Tst deletion results in increased hepatocyte respiration
but impaired medium-chain fat respiration
(A) Electron microscopy images of liver, visualizing mitochondria from ND-fed
C57BL/6J (n = 4) or Tst/ (n = 4) mice.
(B) Seahorse trace representing the mean oxygen consumption rate (OCR),
normalized to protein, by hepatocytes from ND-fed C57BL/6J (n = 6) or Tst/
(n = 6) mice during a mitochondrial stress test.
(C) Respiratory OCR linked to ATP production (oligomycin sensitive) by he-
patocytes from ND-fed C57BL/6J (n = 6) or Tst/ (n = 6) mice, calculated
from (B).
(D) Respiratory OCR relating to proton leak (oligomycin insensitive) by hepa-
tocytes from ND-fed C57BL/6J (n = 6) or Tst/ (n = 6) mice, calculated
from (B).
(E) Reduction of maximal uncoupled respiration following inhibition of LCFA
mitochondrial import using etomoxir (8 mM) from ND-fed C57BL/6J (n = 4) or
Tst/ (n = 4) mice.
(F) Stimulation of maximal uncoupled respiration following addition of MCFA
octanoate (250 mM) from ND-fed C57BL/6J (n = 4) or Tst/ (n = 4) mice.
Data are represented as mean ± SEM. Significance was calculated using an
unpaired two-tailed Student’s t test (C–F); *p < 0.05. See also Figure S7.
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(downregulated by HFD feeding and upregulated with TST defi-
ciency; Figure 3C).
The Tst/ liver proteome and persulfidome converge on
transamination and lipid oxidation pathways
To assess whether conservation of changes at the protein and
post-translational modification levels can illuminate key regula-
tory hubs driving the hepatic phenotype, we ran a congruence
analysis of the proteome and persulfidome. We found that theGO categories ‘‘amino acid,’’ ‘‘lipid metabolism,’’ and ‘‘peroxi-
some’’ were regulated significantly at the protein abundance
and persulfidation levels in Tst/ mice (Table 3).
Tst/ hepatocytes exhibit elevated mitochondrial
respiration and a defect in medium-chain fatty acid
oxidation
Enhanced respiratory sulfide disposal was found from Tst/ he-
patocytes, and enrichment of mitochondrial proteins was sug-
gested from the liver proteome of the Tst/ mice (Table S4).
We therefore sought to determine whether TST deficiency
affected respiratory function and substrate utilization of the hepa-
tocyte. Analysis of electron micrographs prepared from the liver
of ND-fed Tst/ mice and C57BL/6J controls showed morpho-
logically normal mitochondria (Figure 4A). Basal respiration,
comprising ATP-linked and leak respiration, was significantly
higher in hepatocytes from Tst/mice (Figures 4B–4D).Maximal
hepatocyte respiratory capacity and non-respiratory oxygen
consumption were similar between genotypes (Figures S7A and
S7B). In linewith phenotypic convergence followingHFD feeding,
hepatocyte respiration was comparable between genotypes
from HFD-fed mice (Figures S7C–S7H). A unique feature of the
liver from Tst/ mice was a decrease in proteins and persulfida-
tion levels of proteins in lipid oxidation pathways. We therefore
investigated hepatocyte respiration of lipids. Using a low-pyru-
vate (100 mM) medium to reveal respiratory dependency on other
substrates, we showed that CPT1A-mediated mitochondrial
oxidation of endogenous long-chain fatty acids (LCFAs; etomoxir
inhibited) was similar between genotypes (Figure 4E). Next we
bypassed CPT1A-mediated LCFA transfer and revealed a
marked deficit in respiration stimulated by the medium-chain
fatty acid octanoate in hepatocytes from Tst/ mice (Figure 4F).
A similar experiment adding back pyruvate revealed comparable
stimulation of respiration between genotypes (Figure S7I). In
amino acid-free medium, combined glutamine-, aspartate-, and
alanine-stimulated hepatocyte respiration was comparable be-
tween genotypes (Figure S7J).
DISCUSSION
Elevated TST expression in adipose tissue has been identified as
a genetic mechanism driving metabolically protective leanness
in mice (Morton et al., 2016). Conversely, Tst/ mice exhibited
impaired glucose tolerance (Morton et al., 2016). However,
Tst/ mice had a subtle adipose tissue phenotype, suggesting
a non-adipose origin for impaired glucose homeostasis. We
found increased gluconeogenesis, steatosis, and elevated
plasma VLDL triglycerides consistent with a predominantly he-
patic origin for the diabetogenic phenotype. We cannot rule
out a contribution of renal gluconeogenesis to the phenotype,
and future work will address this limitation. Unexpectedly, and
despite the markedly increased circulating sulfide levels (10-
fold), the steady-state sulfide level was normal in the liver of
Tst/ mice. Moreover, we found evidence of multiple mecha-
nisms for increased hepatic sulfide disposal, reduced down-
stream sulfide signaling, and associated underlying molecular
links to an apparently diabetogenic phenotype. Our data suggest
that the liver of Tst/ mice has overshot in its attempt toCell Reports 37, 109958, November 9, 2021 9
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mental metabolic consequences. This involves a combination
of distinct compartmentalized cellular responses, including
increased respiratory sulfide disposal and export of cysteine
and GSH. Upregulation of translation and recruitment of MPST
to mitochondria of Tst/ mice is observed. This response, in
the face of reduced transcription of Mpst, suggests a powerful
post-transcriptional cellular sulfide-sensing mechanism. Inter-
estingly, if MPST is compensating for TST-mediated sulfide
disposal in this context, then it implies a subversion of normal
MPST function away from sulfide production (Módis et al.,
2013; Szabo et al., 2014; Kimura et al., 2017; Nagahara, 2018).
Alternatively, this is a response to a perceived lower-sulfide envi-
ronment. TST levels were also elevated in the liver of Mpst/
mice, providing further support for a reciprocal compensatory
mechanism between these two enzymes (Nagahara et al., 2019).
The unexpected finding of normal hepatic sulfide levels in
Tst/ mice led us to discover that the metabolic phenotype
we observed was driven by the very mechanisms invoked to
maintain sulfide within a normal range rather than sulfide excess
per se. Several observations were consistent with this. For
example, the major amino acid pathways increased in the liver
of Tst/ mice were transaminases involved in metabolism of
GSH that support increased export of sulfur equivalents as
GSH (and cysteine). These same transaminases support gluco-
neogenesis by redirecting Krebs cycle intermediates (Rui,
2014; Qian et al., 2015; Sookoian et al., 2016). Reprogramming
of amino acid metabolism for sulfide disposal with knockon ef-
fects to drive hepatic glucose production are suggested, rather
than any change to amino acid-linked mitochondrial respiration
in hepatocytes. This is supported by the shift in hepatocyte py-
ruvate metabolism toward aspartate. In addition, glutathione
S-transferases (GST) that inhibit gluconeogenesis (Ghosh Dasti-
dar et al., 2018) were lower in the liver of Tst/ mice. Further,
activation of NRF2, which represses gluconeogenesis (Slocum
et al., 2016) appears to be lower in the liver of Tst/ mice.
Involvement of NRF2 in the Tst–/– liver phenotype is further sup-
ported by the phenotype of Nrf2/ mice that similarly exhibited
steatohepatitis in the absence of insulin resistance (Meakin et al.,
2014). However, NRF2 signaling can be complex and dependent
on dietary context; Nrf2/ mice showed improved glucose
tolerance after HFD feeding (Zhang et al., 2012), suggesting
that any contribution of a NRF2 signaling deficit in the liver of
the Tst/ mice changes upon HFD feeding. Beyond altered py-
ruvate flux, we also showed that hepatocytes of Tst/ mice ex-
hibited defective lipid metabolism. Specifically, medium-chain
fatty acid (MCFA) oxidationwas impaired, associated with selec-
tive reduction of the protein and persulfidation levels of lipid
catabolic enzymes. This represents a mechanism linking altered
sulfide metabolism to lipid oxidation, hepatic lipid accumulation,
and dyslipidemia. Consistent with impaired MCFA oxidation de-
fects as one driver of the phenotype, steatosis is observed inme-
dium-chain acyl-CoA dehydrogenase (Mcad) / mice (Tolwani
et al., 2005), and dyslipidemia is found in MCADD-deficient hu-
mans (Onkenhout et al., 1995). The data we present add to a
growing understanding of the link between sulfide regulating
genes and nutrient metabolism that has so far focused on the en-
zymes of sulfide production. Specifically, we provide support for10 Cell Reports 37, 109958, November 9, 2021the importance of the sulfide oxidizing pathway as a regulator of
cellular sulfide exposure. Unexpectedly, the data reveal cellular
mechanisms that are engaged to homeostatically regulate
sulfide disposal and can affect cell energetics and nutrient
metabolism.
Our findings may have implications for potentially unexpected
side effects of sulfide donor therapeutic agents. In normal mice,
in vivo sulfide administration for 4 weeks after HFD feeding
partially reversed hepatic lipid accumulation invoked by chronic
(16 weeks) HFD feeding (Wu et al., 2015). No evidence was pro-
vided regarding whether sulfide disposal mechanisms were
altered (Wu et al., 2015). This efficacious subchronic sulfide
administration regimen contrasts with our genetic model of
chronic sulfide elevation as a driver of dysregulated metabolism
and NAFLD. Clearly, the normal mice in the Na2S administration
studies had a fully functional SOP, suggesting that the presence
of TST is required to achieve the beneficial metabolic effects of
Na2S administration. This is also consistent with the apparently
low sulfide signaling status (evidenced by lower persulfidation
and NRF2 target protein abundance) in the liver of the Tst/
mice. The benefits of elevated sulfide cannot be realized,
perhaps because a major mediator of those effects is missing,
and the alternate mechanisms invoked do not fully compensate
(e.g., MPST) or actively drive aberrant nutrient metabolism.
Comparable studies of glucose and lipid metabolism after
manipulation of other sulfide-regulating genes are limited.
However, in a contrasting model of reduced sulfide production
(Cth/ mice), plasma triglycerides were lowered (Mani et al.,
2013), opposite to what we observed with Tst/ mice. The he-
patic sulfide disposal status of the Cth/ mouse model is un-
known, but our findings predict suppression of the SOP to spare
the limited endogenous sulfide produced. Intriguingly, they also
predict a knockon effect on nutrient homeostasis because of
reduced metabolic demand of the TST/SOP axis. A more direct
model informing on the effects of impairment of the sulfide
disposal pathway is deficiency of the key mitochondrial SOP
enzyme ETHE1. Ethe1/ mice suffer fatal sulfide toxicity (Tiranti
et al., 2009); therefore, comparable metabolic studies are lack-
ing. However, one notable observation is that Ethe1/ mice
have apparently 10-fold higher liver sulfide exposure than control
mice (Tiranti et al., 2009), in contrast to the normalized hepatic
sulfide levels of Tst/ mice. Circulating sulfide levels were not
reported for comparison, but the presumably relatively lower
systemic sulfide levels of Tst/ mice appear to have permitted
an effective homeostatic sulfide disposal response in the liver
to avoid toxicity, albeit with a metabolic cost. Consequently,
the liver of Tst/ mice has a functional and proteomics profile
distinct from that of Ethe1/ mice. For example, in the liver of
Tst/ and Ethe1/ mice (Hildebrandt et al., 2013), proteins of
the GST Mu type (GSTM) and peroxiredoxin (PRDX) families
were altered, but sometimes in the opposite direction or with
alteration of distinct protein subclasses. A notable difference is
also observed in amino acid metabolism. The liver of Ethe1/
mice exhibits increased expression of enzymes of branched-
chain amino acid metabolism (Hildebrandt et al., 2013), distinct
from the predominantly GSH-related amino acid pathways that
are increased in the liver of Tst/ mice. Beyond sulfide, TST
may also have distinct cellular roles that affect metabolism,
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tion ofmitochondrial iron-sulfur clusters (Bonomi et al., 1977; Pa-
gani and Galante, 1983; Nandi and Westley, 1998; Nandi et al.,
2000; Smirnov et al., 2010).
Given the pro-diabetogenic liver phenotype in Tst/ mice, its
was surprising that insulin signaling in the liver appeared normal
and peripheral insulin sensitivity was increased. There are prece-
dents for increased hepatic glucose production independent of
insulin resistance, as found in the Nrf2/ mice (Meakin et al.,
2014) and as driven by the transcription factor carbohydrate-
response element-binding protein (ChREBP) (Uyeda and Repa,
2006; Kim et al., 2016). There is also evidence to support insu-
lin-sensitizing effects of sulfide administration in vivo in mice
and rats (Feng et al., 2009; Geng et al., 2013; Xue et al., 2013),
consistent with sulfide-mediated insulin sensitization of non-he-
patic tissues in Tst/ mice. Higher circulating GSH in Tst/
mice may also promote peripheral insulin sensitization (Jain
et al., 2014; Lutchmansingh et al., 2018). Clearly, the net balance
of glucose production from the liver and its peripheral disposal
remain abnormal in Tst/ mice. Indeed, the baseline metabolic
phenotype of Tst/ mice resembles in many ways that of a
normal mouse fed a HFD, and we showed some overlapping
pro-diabetogenic signatures between the liver proteome of
Tst/ mice and that of HFD-fed C57BL/6J mice. However, we
also found distinct lipid metabolism and peroxisomal protein
changes in Tst/ mice. Unlike a HFD state, which is associated
with dominant hepatic insulin resistance, the increased hepatic
glucose production in ND-fed Tst/mice occurs despite normal
hepatic insulin sensitivity. The significant changes in persulfida-
tion of transaminase and gluconeogenesis proteins suggest that
coordinated cross-talk acrossmetabolic pathways underlies this
atypical metabolic phenotype.
Sulfide donor therapeutic agents have been proposed as a
clinical strategy for improving cardiovascular health (Szabó
et al., 2011; Whiteman et al., 2011; Zhang et al., 2018). Elevated
endogenous sulfide has also been implicated in the beneficial
metabolic effects of caloric restriction (Miller et al., 2005; Hine
et al., 2015, 2017, 2018; Shimokawa et al., 2015; Lee et al.,
2016). Our results suggest that chronic sulfide elevation may
have unintended detrimental consequences, driving liver
glucose production and fat accumulation to undesirable levels.
Fortunately, this may be limited to cases where SOP proteins
are compromised through rare genetic effects, such as TST var-
iants (Billaut-Laden et al., 2006; Libiad et al., 2015). More
broadly, a number of drugs or supplements are known to in-
crease cyanide, which may dominantly inhibit TST activity and
result in secondary sulfide overexposure. These include nitro-
prusside (Morris et al., 2017) and amygdalin (Bromley et al.,
2005; O’Brien et al., 2005). Indeed, the TST metabolite thiosul-
fate is commonly co-administered with nitroprusside to prevent
cyanide toxicity (Curry et al., 1997). Furthermore, dietary and
environmental exposure to cyanogenic compounds (Simeonova
et al., 2004), e.g., smoking (Vinnakota et al., 2012) or cyanogenic
diets (Kashala-Abotnes et al., 2019), may interfere with normal
TST function and could lead to increased sensitivity to sulfide
therapeutic agents. In contrast, we have shown that administra-
tion of the TST substrate thiosulfate can ameliorate diabetes
(Morton et al., 2016), further underlining the potential utility of tar-geting the SOP inmetabolic disease. As with all therapeutic stra-
tegies, a careful cost-benefit analysis is required. A comparable
case of relevance are the statins, one of the most potent and
widely used drugs to prevent atherosclerosis, which also carry
a higher risk for diabetes (Swerdlow et al., 2015). The full effect
of TST manipulation on opposing metabolic pathways requires
further study. Our current study sheds light on the underlying he-
patic mechanisms invoked for sulfide disposal that are relevant
to current sulfide donor strategies and may inform on routes to
reduce their potential metabolic side effects.
Limitations of the study
Although the liver is the site of most (60%) post-absorptive
gluconeogenesis in normal animals within physiological fasting
ranges, renal/small intestinal gluconeogenesis begins to sub-
stantially contribute to circulating glucose with prolonged fast-
ing/starvation (Sasaki et al., 2017; Mutel et al., 2011; Mithieux
et al., 2003; Stumvoll 1998; Owen et al., 1969). We cannot rule
out a role of renal or intestinal gluconeogenesis in the diabeto-
genic phenotype of Tst/ mice. This will be an important area
of future work, although liver TST is at least more than 3-fold
that of the kidneys, and small intestinal TST is very low (BioGPS;
Figure S1A).
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Antibodies
Anti-TST GeneTex GTX114858; RRID:AB_10620797
Anti-MPST Abcam ab224043
Anti-GOT1 Abcam ab170950; RRID:AB_170950
Anti-GSTT1 Proteintech 15838-1-AP; RRID:AB_2116344
Anti-MAT1A Abcam ab129176; RRID:AB_11145300
Anti-BHMT Proteintech 15965-1-AP; RRID:AB_2290472
Anti-CSAD Abcam ab91016; RRID:AB_10713222
Anti-PPCS Atlas Antibodies HPA031361; RRID:AB_10602150
IRDye 800CW Goat anti-Rabbit Li-Cor 926-32211; RRID:AB_621843
IRDye 680RD Donkey anti-Mouse Li-Cor 926-68072; RRID:AB_10953628
Anti-B-Actin Abcam ab8226; RRID:AB_306371
Anti-CoxIV Abcam Ab16056; RRID:AB_443304
Chemicals, peptides, and recombinant proteins
sodium pyruvate 13C3 Sigma-Aldrich 490717
Amyloglucosidase Roche ROAMYGLL
Antimycin A Sigma-Aldrich A8674
B-glycerophosphate Sigma-Aldrich G9422
B-mercaptoethanol Sigma-Aldrich 444203






Oligomycin A Cayman Chemicals 11342
DL-Carnitine hydrochloride Sigma-Aldrich C9500
Collagenase type 1 Worthington Laboratories LS004194
cOmplete, Mini, EDTA-free Protease
Inhibitor Cocktail
Roche 11836153001
Glucose, D-[3-3H] PerkinElmer NET331C





Durcupan ACM Sigma-Aldrich 44610
(+)- Etomoxir sodium salt hydrate Sigma-Aldrich E1905
EZ-link Maleimide-PEG2-Biotin Thermo Fisher Scientific 21901BID
Fetal Calf Serum, Brazilian Origin SLS Life Science HYC85
Prestained Protein Marker Proteintech PL00001
Glutamax Thermo Fisher Scientific 35050061
L-Glutamine Sigma-Aldrich G7513
Glycine Sigma-Aldrich 50046
Hematoxylin solution Abcam Ab220365
Iodoacetamide Sigma-Aldrich I1149
L-cysteine Sigma-Aldrich 30089
Lead citrate, tribasic trihydrate Sigma-Aldrich 15326
Malate dehydrogenase, porcine heart Sigma-Aldrich 442610-M
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Skim Milk Powder Millipore 70166
S-Methyl methanethiosulfonate Sigma-Aldrich 64306
MitoSOX Red Mitochondrial superoxide
indicator
Thermo Fisher Scientific M36008
NADH, Grade I disodium salt Roche 10107735001
Pierce NEM (N-ethylmaleimide) Thermo Fisher Scientific 23030
Sodium octanoate Sigma-Aldrich C5038
Oil Red O Sigma-Aldrich O0625
Oligomycin A Sigma-Aldrich 75351
Penicillin Streptomycin Thermo Fisher Scientific 15140122
PERCOLL 8.5-9.5 Sigma-Aldrich P1644
Phosphoenol pyruvate Roche 10108294001
cOmplete protease cocktail inhibitor Roche 04693159001
Rat tail collagen 1 Sigma-Aldrich 08-115
REVERT total protein stain LICOR 926-11011
Rotenone Sigma-Aldrich R8875
Sequencing grade modified Trypsin Promega V5111
Sodium fluoride Sigma-Aldrich S7920
Sodium L-lactate Sigma-Aldrich 71718
Sodium orthovanadate Sigma-Aldrich 450243
Sodium pyrophosphate Sigma-Aldrich 221368
Sodium pyruvate Sigma-Aldrich P8574
Sodium sulfate Sigma-Aldrich S9627
Sodium thiosulfate Sigma-Aldrich 563188
Sodium sulfide Sigma-Aldrich 407410
Sulforhodamine B dye Sigma-Aldrich 230162
Taurine Sigma-Aldrich 86329
Tetrabutylammonium phosphate Sigma-Aldrich 86833
Trichloroacetic acid Sigma-Aldrich T6399
Triethylammonium bicarbonate Sigma-Aldrich 18597
Trifluoracetic acid Sigma-Aldrich 80457
Uranyl acetate Electron Microscopy Sciences 22400
Urea Sigma-Aldrich U5128
XF Seahorse Base Media (DMEM) Agilent 102353-100






Infinity Triglyceride Assay Thermo Fisher Scientific TR22421
Infinity Cholesterol Assay Thermo Fisher Scientific TR13421
Glucose Hexokinase Assay Abcam Ab136957




Experimental models: Cell lines
Primary hepatocytes C57BL/6J and Tst–/– mice n/a
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Experimental models: Organisms/strains
C57BL/6J (JAX mice strain) Charles River Strain code: 632
Tst—/— C57BL/6N mouse (backcrossed for
> 10 generations at University of Edinburgh)
University California (Davis)
International Mouse Knockout Project
VG13928; model Tsttm1(KOMP)Vlcg
Oligonucleotides
Tst (mouse) FAM gene expression assay
4331182
Thermo Fisher Mm00726109_m1
Mpst (mouse) FAM gene expression assay
4331182
Thermo Fisher Mm00460389_m1
Gapdh (mouse) FAM gene expression
assay 4331182
Thermo Fisher Mm99999915_g1





Graph Pad Prism v8, 9 and 10 N/A
Other
Amersham Hybond P blotting membranes,
PVDF
Merck GE10600021
Microvette CB300 K2E EDTA tubes Sarstedt 16.444.100
Ultra-0.5 centrifugal filter, 10K cut off Millipore UFC501096
Streptavidin-agarose beads Thermo Scientific 20347
Formvar coated grids Agar Scientific AGS138
Standard rodent diet SDS RM1
Cornstarch diet Research Diets D12383





Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Nicholas
M. Morton (nik.morton@ed.ac.uk).
Materials availability
No other new unique reagents were generated for the production of the data in this paper.
Data and code availability
d Proteomics and persulfidomics root data from the iTraq and persulfidated peptide mass spectrometry experiments have been
deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset
identifier ProteomeXchange: PXD028909.
d This paper does not report original code.
d Any additional information required to reanalyse the data reported in this paper is available from the lead contact upon request.EXPERIMENTAL MODEL AND SUBJECT DETAILS
Experimental animals
All experiments were performed according to guidelines set out by the ethical committees of The University of Edinburgh and Physi-
ogenex S.A.S, Prologue Biotech, Labége, FRANCE. Experiments were carried out within the framework of the Animals (Scientific Pro-
cedures) Act (1986) of the United KingdomHomeOffice or related laws from the EuropeanUnion (France). In all studies, animals within
genotype cohortswere randomly assigned to diet or intervention groups. All animals weremaintained in standard housingwith 12 hour
light and12 hour dark cycles (7 a.m. to 7 p.m.) and ad libitum access to the appropriate diet. For in vivoexperiments (pyruvate tolerancee3 Cell Reports 37, 109958, November 9, 2021
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OPEN ACCESStest, insulin tolerance test, euglycaemic clamps), operators and animal handlers were blinded to the data, which was generated by a
second individual who was blinded to the treatment regimen until the code was broken. All of the studies used male mice housed in
cages of 3-6 individual littermates until intervention. The mice for this study originated from C57BL/6N Tst—/— mice (Morton et al.,
2016) backcrossed onto the C57BL/6J genetic background for > 10 generations. Mice were placed onto high fat diet D12331, (58%
calories from fat, Research Diets, New Brunswick, USA) frombetween 6-8 weeks of age, for 6-7 weeks prior to testing, and compared
to mice maintained on standard low fat diets, RM1 or D12383 (low-fat high-cornstarch, Research Diets, New Brunswick, USA).
Hepatocyte preparations
Mice were killed by CO2 asphyxiation, followed by cervical dislocation. The chest cavity was opened, the portal vein was cut and the
thoracic vena cavawas cannulated via the right atrium. The liverwasperfusedwith (37C) perfusionmedia (140mMNaCl, 2.6mMKCl,
0.28mMNa2HPO4, 5mMglucose, 10mMHEPES, 0.5mMEGTA, pH7.4), 6mls/min for 10min. The liverwas thenperfusedwith diges-
tionmedia (perfusion media, without EGTA, including 5mMCaCl2, and 100 U/ml collagenase type 1) for 5-7min. Finally, the liver was
perfused with perfusion media for a further 10 min. Cells were extruded from liver into DMEMmedium (DMEM, 5.5 mM glucose, 10%
FCS, 7 mM glutamine, and penicillin/streptomycin antibiotics), and then passed through a 40micron filter. Cells were spun twice and
washedwithmedium,at 500 rpm (47g) for 5min.Cellswere spun througha50%Percoll pH8.5-9.5/DMEMsolution at 1000 rpm (190g)
for 15min to remove dead cells and non hepatocytic liver cell types. Hepatocytes collected in the pellet fractionswere resuspended in
medium and spun twice with washing at 500 rpm (47 g) 5 minutes. Yields and viability were assessed by counting using a haemocy-
tometer, andproportion of trypanblue exclusion respectively. Yields ranged frombetween23106 – 1.53107 viable cells, and viability
was above 85%. Unless otherwise stated, hepatocytes were seeded onto collagen coated tissue culture plastic (collagen from rat
tails, Sigma), and maintained in DMEM with 5.5 mM glucose, 10% FCS, 7 mM glutamine, and antibiotics).
METHOD DETAILS
Pyruvate tolerance test
Blood glucose was measured from 16 hour fasted mice before (0 time) and following bolus sodium pyruvate administration
(i.p. 1.5 mg/g bodyweight). Blood was collected following tail venesection at 0, 15, 30, 60 and 120 minutes after injection. Glucose
was measured from blood using a Glucometer (OneTouch, Lifescan, Milpitas, USA or Accu-Chek, Performa nano, Roche).
PEPCK activity assay
Activity of phosphoenolpyruvate carboxykinase was measured from cytosol samples obtained from frozen liver. Samples were ho-
mogenized in 250 mM sucrose, 5 mM HEPES, pH 7.4. and centrifuged at 4C, 12,000 rpm (17,390 g) for 15 min. Supernatants were
ultracentrifuged at 4C, 60,000 rpm (289,000 g) for 30 min. Activity of PEPCK from cytosolic fractions was inferred in this assay from
NADH extinction, linked to the conversion of phosphoenol pyruvate into oxaloacetate in the presence of carbonate, dGDP and
MnCl2, and the subsequent conversion of oxaloacetate into malate by adding malate dehydrogenase. Baseline measurements at
340 nM (NADH) were taken for 20 min before adding phosphoenol pyruvate, and the reaction proper was initiated with dGDP.
The reaction was then measured for a further 40 min.
13C Pyruvate metabolite tracing
After overnight culture on collagen coated 6-well tissue culture plates, hepatocytes were incubated with 1 mM 13C3 labeled pyruvate
in serum free DMEM for 60 min. Metabolites were extracted by washing individual wells with ice-cold PBS and addition of cold
extraction buffer (50% methanol, 30% acetonitrile, 20% water solution at 20C or lower). Extracts were clarified and stored at
80Cuntil required. LC-MSwas carried out using a 100mmx4.6mmZIC-pHILIC column (Merck-Millipore) using a ThermoUltimate
3000HPLC inline with a Q Exactive mass spectrometer. A 32min gradient was developed over the column from 10%buffer A (20mM
ammonium carbonate), 90% buffer B (acetonitrile) to 95% buffer A, 5% buffer B. 10 mL of metabolite extract was applied to the col-
umn equilibrated in 5% buffer A, 95% buffer B. Q Exactive data were acquired with polarity switching and standard ESI source and
spectrometer settings were applied (typical scan range 75-1050). Metabolites were identified based upon m/z values and retention
time matching to standards.
Plasma lipid analysis
Mice were fasted with free access to water for 4 hours prior to cull by decapitation or pentobarbital euthanasia. Trunk blood (decap-
itation) was collected directly into Sarstedt Microvette CB 300 K2E EGTA containing plasma sample tubes (Sarstedt, N€umbrecht,
Germany). Venous blood from the abdominal vena cava (post euthanisation) was collected into a BD Plastipak 1 mL syringe (BD,
Madrid, Spain). This was then transferred to Sarstedt EGTA containing sample tubes for centrifugation. Blood samples obtained
by eithermethodwere centrifuged at 20Cand 5000 rpm (2655 g) for 5min to obtain plasma samples. Plasma sampleswere analyzed
for cholesterol and triglyceride content by as previously described (Peters et al., 1997). Briefly, samples were subjected to gel filtra-
tion chromatography using an integrated Alliance HPLC separations module (e2695, Waters, Milford, US) to separate lipoproteins
based on size. Effluent was immediately and continuously mixed with either triglyceride (Infinity Triglyceride, Thermo Scientific,
Loughborough, UK) or cholesterol (Infinity Cholesterol, Thermo Scientific, Loughborough, UK) enzymatic colormetric detectionCell Reports 37, 109958, November 9, 2021 e4
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spectrophotometer at the appropriate wavelength and the signal turned into a continuous trace i.e., a lipid profile. By identification of
the lipoprotein peaks (based on their time of emergence from the chromatograph) the concentration for each could be calculated.
Oil Red-O lipid analysis of liver
5mmcryostat cut frozen sectionsof liverwerecollected ontoSuperfrost slides (Thermo), and rinsedwith 60% isopropanol. Slideswere
incubated in freshly prepared staining solution (2.1 mg/ml Oil Red O in 40% isopropanol/water) for 10 – 30 min and rinsed with 60%
isopropanol. Slides for representative images were counterstained for nuclei in hematoxylin (Harris) for 1 minute. For image analysis,
slides were not counterstained. All slides were then rinsed in running tap water for 2 min, before mounting. Sections were captured
using an AxioScan Z1 slide scanner at 3 40 magnification and analysis of the proportional area of Oil Red O staining (area of stain/
unit area of section) was performed using ImageJ software (National Institutes of Health), assessed by a blinded assessor.
Liver Glycogen measurement
Frozen liver samples (between30-90mg)were heated to 100C in anEppendorf tubewith 0.3mls of 30%KOH for 30minwith vigorous
shaking at 10-min intervals. Samples were heated for a further 2-3 min after addition of 0.1 mL 1MNa2SO4 and 0.8 mL ethanol. Sam-
ples were then centrifuged at 4C at 1011 g for 5 minutes. The supernatant was removed, and the pellet resuspended in distilled H2O
before 0.1mL1MNa2SO4and0.8mLethanolwere again added, and samplesboiled at 100
C for 5minbefore centrifugation. Thiswas
repeated a final time to wash the sample. The pellet was resuspended in a 10mg/ml (1200 U/ml) amyloglucosidase enzyme in 0.3M
sodium acetate (pH 4.8). Samples were then incubated at 50C for 2 hours. Quantification of samples was then performed using a
standard hexokinase based glucose assay (Glucose (HK) Assay Kit, Sigma, GAHK20). The assay was performed following manufac-
turer’s instructions and values calculated by extrapolation from a standard curve after measuring absorbance using a plate spectro-
photometer (Molecular Devices OPTImax microplate reader and software, Molecular Devices, Wokingham, UK).
Western blotting for protein abundance
Frozen liver samples (stored 80C) from mice were homogenized in protein lysis buffer (50 mM Tris, 270 mM sucrose, 50 mM
NaF, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 10 mM B-glycerophosphate, 5 mM Na Pyrophosphate, 1 mM orthovanadate,
0.1% b-Mercaptoethanol, 1 tablet protease inhibitor cocktail inhibitor, pH 7.4, all Sigma Aldritch). Samples were then centrifuged at
13,200 rpm (18500 g) for 15 min at 4C and the supernatants aliquoted and stored at 80C. Protein samples were loaded onto
10%acrylamide/bis-acrylamide gels (30%acrylamide, SigmaAldritch) and separated by electrophoresis. A coloredmolecular weight
marker was also run on all gels (Full range rainbowmolecular weightmarkers, GEHealthcare). Gels were transferred overnight using a
Bio Radwet transfer system onto AmershamHybond – Pmembranes (GEHealthcare). After transfer, for normalization of specific tar-
gets to total protein, membranes were stained using the REVERT total protein stain (LICOR), according to manufacturers’ instruction.
Following stain and wash, lanes of each sample were analyzed using a LI-COR Odyssey scanner (700nm channel). For blots using a
house keeping protein for normalization, the total protein stain was not performed, andmembraneswere transferred directly to block-
ing. All membranes were blocked in Tris buffered saline with 0.01% tween (TBST, containing 5% skimmed milk powder (Marvel
skimmedmilk powder) for 1 hour and then rinsed in TBST.Blockedmembraneswere then incubatedwith the appropriate primary anti-
body in TBST containing 5%BSA (Sigma Aldritch) overnight at 4C. Following three 5 min washes with TBST, secondary antibody in-
cubation for all blots was with an appropriate green or red fluorescent antibody, incubated at room temperature for 2 hours in TBST
containing 5% BSA. Membranes were washed three times in TBST then scanned using the LI-COR Odyssey scanner. Odyssey
software (LI-COR Biosciences) was used to quantify band intensity. For normalization to a house keeping protein, the individual
band intensity ofB-actinwasused for each sample.Primary antibodies usedwere; TST,Rabbit, GeneTex,GTX114858,MPST,Rabbit,
Abcam, Ab224043, GOT1, Rabbit, Abcam, ab170950, GSTT1, Rabbit, Proteintech, 15838-1-AP, MAT1A, Rabbit, Abcam, ab129176,
BHMT Rabbit, Proteintech, 15965-1-AP, CSAD, Rabbit, Abcam, ab91016, PPCS Rabbit, Atlas Antibodies, HPA031361. Secondary
antibodies used were; IRDye800CW Goat anti-Rabbit, Li-Cor, 926-32211, IRDye 680RD Donkey anti-Mouse, Li-Cor, 926-68072.
For normalization B-Actin, Mouse, Abcam, ab8226 was used for whole tissue, and Cox IV (mitochondrial loading control), Abcam,
ab16056 was used for mitochondrial fractions.
Insulin tolerance test
Male C57BL/6J or Tst—/—mice weremaintained on standard chow (RM1). Mice were fasted for 4 hours prior to injection i.p. of insulin
(1 mU/g bodyweight, NovoRapid 100U/ml, Novo Nordisk). Tail venesection blood samples were taken prior to, and 15, 30, 60 and
120 minutes post injection. Blood glucose was measured from samples using a Glucometer (Accu-Check, Performa Nano, Roche).
Blood glucose was plotted across time to evaluate net glucose accumulation in blood.
Euglycemic hyperinsulinemic clamps
MaleC57BL/6J or Tst—/—miceweremaintained on standard diet (RM1 (E) 801492, SDS) or high fat diet for 6weeks (58% fat, D12331,
Research Diets). Prior to performing the hyperinsulinemic euglycemic clamp an indwelling catheter was placed into the femoral vein
under isoflurane anesthesia, sealed under the back skin, and glued onto the top of the skull. Clamps were performed 5-6 days after
recovery from catheterization. Mice were fasted 6 hours prior to a basal blood sample was taken for glucose and insulin. Mice thene5 Cell Reports 37, 109958, November 9, 2021
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basal phase and hyperinsulinemic clamp). At steady state (60 min after start of perfusion), 5 ml of blood was collected and glycemia
measured from tail tip every 10min over 30 min for 3H-radioactivity analysis for determination of whole body glucose turnover glycol-
ysis and glycogen synthesis rate in the basal state. 90 min after start of perfusion, the hyperinsulinemic clamp starts by co-perfusion
with insulin 8 mU/kg/min for the clamped phase over 120 min. Blood glucose was assessed every 10 minutes, and glucose infusion
adjusted until steady state bloodglucose (120mg/dl±10mg/dl) was achieved. 5ml of bloodwascollected from, tail tip every 10min for
3H- radioactivity analysis. At 150min after the start of perfusion, a bolus of 14C-2-deoxyglucose (25 mCi) was perfused to evaluate tis-
sue specific uptake. At the end of the perfusion (210min), blood is collected from the retro-orbital sinus tomeasure plasma insulin and
mice sacrificed by i.v. injection of pentobarbital and cervical dislocation. Tissues (Inguinal WAT, Epididymal WAT, Soleus muscle,
Extensor digitorum longus muscle, Vastus lateralis muscle, Tibialis anterior muscle, Heart apex, Liver) were removed by dissection
and flash frozen in liquid nitrogen (stored 80C until measured). Tracers were used to calculate various aspects of glucose meta-
bolism (Steele et al., 1956; Carter and Morton, 2016). Parameters measured or calculated include body weight, glucose infusion
rate, whole body turnover, hepatic glucose production, whole body glycolytic rate, whole body glycogen synthesis rate, and tissue
glucose utilization.
MBB derivatization of whole blood and plasma
Whole blood was taken after cull of mice, from trunk (following decapitation), or portal vein (following CO2 euthanasia). EDTA-plasma
was obtained from trunk blood following decapitation and collected onto ice. Blood for plasma was centrifuged within 15 min of
collection for 5 min at 5000 rpm (2655 g) at 4C. Blood and plasma samples (15-50 ml) were derivatized with monobromobimane
by addition of 200 mL of 80 mM EPPS (4-(2-Hydroxyethyl)-1-piperazine propanesulfonic acid, 8 mMDTPA (diethylenetriaminepenta-
acetic acid) pH 8.0, 50% acetonitrile, 2.3 mMmonobromobimane. Reaction vials were capped tightly and vortexed for 1 minute and
incubated protected from light at room temperature for 30min. 1mL ethyl acetate was added, the tube capped and vortexed for 1min
and incubated protected from light for 10 min. The reaction vials were centrifuged at 1800 rpm (350 g) for 7 min to separate aqueous
and organic layers. The organic layer was collected from each extraction, transferred to a 1.5mL brown glass vial and the solvent was
evaporated completely under a nitrogen stream. Acetonitrile (200 mL) was added to each vial, and the solvent was again evaporated
to remove any traces of ethyl acetate. Dried MBB-derivatives were stored at 20C until analyzed.
Fluorometric quantification of MBB-sulfur species
MBB-sulfur species (sulfide, thiosulfate, reduced glutathione, and cysteine) in samples was quantified by HPLC separation and
detection with a fluorescence detector. The dried MBB derivatives were re-suspended in 50 mL of Buffer A (10 mM tetrabutylammo-
nium phosphate aqueous, 10% methanol, 45 mM acetic acid adjusted to pH 3.4). The entire sample was transferred to an HPLC
autosampler vial with a 200 mL glass sample insert, and the vial was closed with a penetrable cap. 20 mL of the sample was injected
onto a C8 reverse-phase column (LiChrospher 60 RP-select B 5 mm 4.0 3 125 mm LiChroCART 125-4, Merck KGaA) and a guard
column (LiChroCART 10-2, Superspher 60 RP-select B cartridge) on an Ultimate 3000 UHPLC+ focused system (Thermo Scientific).
MBB derivatives were eluted with a linear gradient from 10% buffer B (10 mM tetrabutylammonium phosphate in methanol, 10%
water, 45 mM acetic acid) to 100% buffer B over 30 min. The eluent was analyzed by fluorescence (lex = 380 nm, lem = 480 nm).
Sulfur metabolite analysis from liver
Livers from mice were removed promptly following decapitation (within 2 min), and frozen on powdered dry ice. Frozen tissue was
pulverized and derivatized with either 2,4-dinitrofluorobenzene for detecting GSH or monobromobimane for detecting sulfide and
thiosulfate as described previously (Mosharov et al., 2000; Vitvitsky et al., 2006, 2015).
P3 fluorescence detection of sulfide in hepatocytes
Hepatocytes were seeded in glass bottomed, collagen coated wells (0.75 cm2, 12,500 hepatocytes per well) and cultured in DMEM
with 5.5 mM glucose, 10% FCS, 4 mM glutamax or 7 mM glutamine, and antibiotics overnight. P3 H2S reactive probe (Singha et al.,
2015) was added to wells at 10 mM in serum free DMEM for 30 min, prior to gentle washing with Krebs phosphate buffered saline
(pH 7.4). Plates were measured using the TECAN fluorescence plate reader, following excitation at 375 nm and detection at
510 nm. No-cell control wells were used for subtracting from the cell containing values. Corrected fluorescence emission data
was normalized to protein as estimated by sulforhodamine dye. Briefly, after the run cells were fixed with 10% trichloroacetic
acid overnight at 4C. Cells were washed 9 times with tap water, and air-dried. Cells were incubated with 200 mL of 0.4% Sulforhod-
amine dye/1% acetic acid for 1 hour at room temperature. Stain was removed, and washed 4 times with 1% acetic acid, and then
air-dried. Stain was dissolved in 200 mL of 10 mM Tris pH 10.5 for 30 min, and 100 mL was measured by colorimetric absorbance
spectroscopy at 540 nm. After subtracting a baseline absorbance from blank controls, the absorbance was used to normalize the
fluorescence data from each well.
Quantification of hydrogen sulfide levels using MitoA in vivo exomarker
MitoA andMitoNwere quantified inmouse blood using LC-MS/MS.Mice received a tail vein IV injection of 50 nMMitoA in 0.9% saline
(100 mL). MitoA was given 1.5 hr to distribute into mitochondria. Mice were culled by decapitation 90 minutes after administration.Cell Reports 37, 109958, November 9, 2021 e6
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enriched with 5 pg d15-MitoN (95% ACN, 210 mL) which was used as an internal standard (IS). Homogenates were centrifuged
(16,000 g, 10 min, RT) and the supernatant was transferred to a clean tube and stored on ice. The pellet was re-extracted (95%
CAN, 210 mL), spun down again (16,000 g, 10 min, rT) and the supernatants were combined and incubated at 4C for 30 mins. Cali-
bration standards comprise MitoA and MitoN standards ranging from 0.01 to 10 pg in 500 mL 95% ACN. 500 mL of the supernatants
and calibration standards were loaded onto an ISOLUTE PLD+ protein and phospholipid removal plate (Biotage, Sweden). Samples
and standards were pulled through the plate under vacuum into a 2 mL deep-well 96-well plate. Wells were dried completely at 40C
under N2 and resuspended in 100 uL 20% ACN, 0.1% FA. The plate was shaken at (250 rpm, 20 min) to ensure reconstitution. Liquid
chromatography-Mass Spectrometry was performed on an I-class Acquity LC system-Xevo TQS triple quadrupole mass spectrom-
eter (Waters, Warrington, UK). Samples were kept at 10C and injected onto an Acquity UPLC BEH C18 column fitted with a 0.2 mm
filter (13 50mm, 1.7 mm,Waters). Chromatographic separation ofMitoA andMitoNwas achieved usingmobile phase A composition:
water:ACN, (95:5, 0.1% FA), mobile phase B: ACN:water (90:10, 0.1% FA). LC mobile phases were infused at 200 mL/min using the
gradient: 0– 0.3 min, 5% B; 0.3–3 min, 5%–100% B; 3– 4 min, 100% B, 4.0– 4.10, 100%–5% B; 4.10– 4.60 min, 5% B. MS/MS anal-
ysis was performed under positive ion mode (Source spray voltage, 3.2 kV; cone voltage, 125 V; ion source temperature, 100C).
Curtain and collision gas were nitrogen and argon, respectively. Analytes were detected by multiple reaction monitoring (MRM). Mi-
toA undergoes neutral loss of N2 to a nitrene (precursor ion). For quantification the following transitions were used: MitoA,m/z 437.2
/183.1; MitoN,m/z 439.2/ 120.0; d15-MitoN, 454.2/ 177.1 m/z. MassLynx 4.1 software was used to integrate the peak area of
the analytesMitoA,MitoN and the d15-MitoN internal standard. Responsewas calculated by normalizing sample peak areas to the IS
peak area. By comparison of sample responses to calibration standard responses the mass of each analyte in the tissue sample was
calculated. The mass of analyte was normalized to the mass of tissue homogenizer and MitoN/MitoA ratio was calculated.
Preparation of hepatic mitochondria
Fresh liver was taken from mice, and homogenized in 250 mM sucrose, 10 mM HEPES, 1 mM EGTA. 0.5% fatty acid free bovine
serum albumin (BSA) pH 7.4 at 4C, with seven passes of a loose glass Dounce homogenizer (Type A). Homogenates were centri-
fuged in glass tubes at 2900 rpm (1000 g) for 10 min in a pre-chilled 4C Beckman centrifuge (JA-20 Fixed angle rotor). The super-
natant was then centrifuged in glass tubes at 8500 rpm (8700 g) for 10min at 4C. The supernatant was aspirated and any visible lipid
was carefully removed from the sides of the tubes. The pellet was washed with 5 mL of mIR-05 buffer (0.5 mM EGTA, 3 mMMgCl2,
20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, 110 mM sucrose, 1 mg/ml fatty acid free BSA, pH 7.2), and centrifuged at 8500 rpm
(8700 g) for 10 min at 4C. After aspiration and removal of visible lipid, the pellet was suspended in 1ml of mIR-05 buffer and kept on
ice until used. All measurements were taken within two hours of preparation. Protein concentration was determined using the
DC-Protein Assay (BioRad) as per manufacturers instruction.
Amperometric analysis of sulfide disposal
Hepatocytes were prepared as described, and kept at room temperature in DMEMwith 5.5 mM glucose, 10% FCS, 4 mM glutamax
or 7mMglutamine, and antibiotics at a concentration of 43 106 perml. Mitochondria were prepared as described, andmaintained on
ice in mIR-05 buffer until use. All samples were analyzed within 4 hours of preparation. Sulfide (H2S(g)) was measured (with and
without samples) in a 2ml volume plastic chamber, to which an amperometric sensor was inserted, sealed with a rubber O-ring.
Voltage measurements from the sensor (linear relationship to H2S(g) concentration) were recorded using a TBR4100 Gas radical
analyzer (World Precision Instruments). A gas permeable membrane covered the sensor, and the outer glass sensor compartment
was filled with H2S detection fluid (World Precision Instruments). All measurements of H2S(g) from standards and samples were re-
corded as voltage by the amperometric sensor at ambient temperature. Mitochondrial measurements (and standards) were taken in
serum free mIR-05 buffer. Hepatocyte measurements (and standards) were taken in serum-free, bicarbonate-free DMEM, buffered
with 25mMHEPES (pH 7.4), with 5mMglucose, 2mMglutamax and 2mMpyruvate. Sulfide was added to buffer in the form of Na2S,
predicted to equilibriate according to its Pka at this pH to about 1/3 of sulfide as H2S(g) 2/3 as HS
-. The probes selectivity to H2S(g)
(versus HS-) was confirmed with standards by demonstrating predicted signal amplification to a maximum following acidification of
media to pH < 5 (approx. 100%H2S(g)/0% HS
-), and signal compression to a minimum following alkalinisation of standard to pH > 10
(Approx 0%H2S(g)/100%HS
-/S2-). A final re-acidification recovered the signal to nearmaximal levels. Standard curves for calculating
experimental measurements were prepared using freshly made Na2S solutions ranging from 0.25 – 20 mM (corresponding to approx-
imately 170 nm – 6.7 mM H2S(g)). H2S(g) disposal was measured by recording the extrapolated H2S(g) concentration after 10 min
incubation with samples. A baseline without sample was taken for 5 min, and then after sample addition (400,000 hepatocytes, or
1.6 – 2.0mg ofmitochondrial prep), another 5min baseline with sample was taken. In all experiments, no detectable increase in signal
(limit of detection 0.25 mM Na2S) was observed during incubation of hepatocyte or mitochondrial samples from either genotype.
Following addition of 10 mMNa2S the (voltage) signal was recorded over a period of 10 min. Disposal rates were calculated after sub-
traction of a baseline disposal rate in media alone, over a 10 min period, performed each day of experimentation. Sample disposal
rates were in the range of 5-20 higher than baseline disposal rate confirming good signal to noise. To determine the rate of disposal
that is dependent upon respiration, a fresh aliquot of the same sample was prepared as before, but 5 min after addition of sample to
chamber, Antimycin A (2.5 mM, dose titrated) was added. After a further 5 minutes, 10 mMNa2S was added and a disposal rate (after
subtraction to sample free baseline rate) was again calculated. The respiratory (Antimycin sensitive/complex III dependent) sulfidee7 Cell Reports 37, 109958, November 9, 2021
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measurement, the sample was removed, and centrifuged to collect cells or mitochondria for a final protein assessment (DC-Protein
Assay, Bio-Rad) for the purposes of normalization.
Mitochondrial ROS (MitoSOX) measurement in H2O2 treated hepatocytes
Hepatocytes were seeded overnight onto 96-well collagen coated plates. Cells were exposed to a range of concentrations of H2O2
(0.125 - 8 mM) for 2 hours. Following 3 washes with PBS, cells were incubated with MitoSOX Red mitochondrial superoxide indicator
(Thermo Fisher) for 10 mins prior to three further washes. Measurement of fluorescence was carried out in a fluorescence detector
plate reader (TECAN), using 510 nm for excitation and 580 nm for emission detection. Data from each well was normalized to sulfur-
hodamine dye protein stain.
Persulfidation Mass Spec and GO term analysis
Livers frommice were removed promptly following decapitation (within 2 min), and snap frozen in liquid nitrogen. The persulfide pro-
teome analysis using the BTA method was conducted as described previously (Gao et al., 2015). Briefly, 100-150 mg of frozen liver
tissue was pulverized and lysed on ice in RIPA buffer (100 mM Tris, pH 7.5, 150 mM NaCl, 2mM EDTA, 1% Triton X-100, 25 mM de-
oxycholic acid, 2 tablets/ 100 mL of cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail (Roche)). The lysates were centrifuged at
14,000 g for 10 min at 4C and protein concentrations were determined using the Bradford reagent (BioRad). Supernatant containing
6mg of protein was incubated with 100 mMNEM-biotin (Pierce) for 60 min at room temperature after which the proteins were precip-
itated with cold acetone (1:4 v/v) for 1 h at20C, followed by a centrifugation at 14,000 g for 10 min at 4C. The precipitated protein
was re-suspended in a denaturing buffer containing 7 M urea, 1% SDS, 150 mMNaCl, 100 mM Tris, pH 7.5. Then, the samples were
diluted 10-fold with trypsin reaction buffer (1 mM CaCl2, 100 mM Tris pH 7.5) and incubated overnight with sequencing grade modi-
fied trypsin (1:50 trypsin:protein) (Promega) at 30C. The digestion products were mixed with streptavidin-agarose beads (Thermo-
Scientific) and incubated at 4 overnight, followed by tenwasheswith thewash buffer (0.1%SDS, 100mMTris, pH 7.5, 600mMNaCl,
1 mM EDTA, 1% Triton X-100). The streptavidin-agarose bound peptides were incubated with elution buffer (100 mM Tris, pH 7.5,
150 mM NaCl, 1 mM EDTA, 30 mM DTT) for 1 hr at room temperature. Persulfidated peptides were eluted by centrifugation and de-
rivatized with 40 mM iodoacetamide for 2 hr at room temperature in the dark. The samples were then passed through a desalting
column (Pierce). LC-MS/MS analysis was carried out using an LTQ-Orbitrap Elite mass spectrometer (Thermo-Fisher) coupled to
an Ultimate 3000 high-performance liquid chromatography system. The alkylated peptides were loaded onto a 75 mm desalting col-
umn, C18 reverse phase resin (Dionex), and eluted onto a Dionex 15 cm x 75 mm id Acclaim Pepmap C18, 2 mm, 100 Å reverse-phase
chromatography column using a gradient of 2%–80% buffer B (5% water, 95% acetonitrile, 0.1% formic acid) in buffer A (0.1% for-
mic acid). The peptides were eluted onto the mass spectrometer at a flow rate of 300 nl/min and the spray voltage was set to 1.9 kV.
GO enrichment analysis
In order to identify differentially persulfidated proteins between the C57BL/6J and Tst—/— samples, we compared the abundances of
persulfidated fragments in appropriately treatedmass spectrometry datasets to the estimated overall abundance of the correspond-
ing parent proteins in standard label-free quantitation experiments. For each observed persulfidated fragment in each experimental
replicate, we calculated the persulfidation rate as the log2 ratio of the count of that persulfidated fragment to themedian count of that
fragment across all experimental replicates. The observed counts for the Tst—/— replicates were additionally scaled (prior to log
transformation) by the ratio of abundances of the parent protein between the C57BL/6J and Tst—/— cells to normalize for differential
protein abundance across conditions. For each peptide we then assigned an approximate average log2 fold change in persulfidation
rate between the C57BL/6J and Tst—/— conditions. If a persulfidated peptide was identified in at least two biological replicates of one
condition and none in the other, we assigned a log2 fold change of ± 5.0 as placeholder values indicating a high confidence change;
peptides with only one observation in one condition and none in the other were omitted from our analysis. Having thus obtained es-
timates for the magnitude of changes in persulfidation rate of each detectable peptide, we then performed gene ontology term
enrichment analysis using the estimated log2 fold changes. We consolidated the peptide-level data to protein-level data by taking
the largest magnitude change in persulfidation levels across all peptides from a given protein, and then used the iPAGE program
[https://dx.doi.org/10.1016/j.molcel.2009.11.016] to identify GO terms with significant mutual information with the profile of persul-
fidation rates. Arguments to iPAGE were ‘‘—max_p=0.1 –minr=0.3 –ebins=9 –exptype=continuous,’’ indicated that the data were
discretized into nine equally populated bins prior to analysis, and that default hypergeometric p value and information content thresh-
olds were relaxed to maximize sensitivity.
Focused analysis of persulfidation in gluconeogenesis proteins
The gluconeogenesis pathway was selected for a focused analysis of the persulfidation rate of all cysteine sites detected in the mass
spectrometry data as described above. All peptides from proteins present in the persulfidation dataset used for GO enrichment anal-
ysis, that are defined by the GO term gluconeogenesis (GO 0006094) were included, these were Pgk1, Gpi1, Fbp1 and Tpi1 (22 pep-
tides). The log2 rate ratio of persulfidation (Tst
—/— /6J) of all of these 22 peptides was compared first to the entire mass spectrometry
dataset for log2 rate ratio of persulfidation (1245 peptides after removal of ambiguous peptides, peptides with a P-diff of 0, and the 22
gluconeogenesis peptides). A Mann-Whitney non parametric t test was used to detect significance. A second analysis wasCell Reports 37, 109958, November 9, 2021 e8
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tude of change in the Tst—/— relative to 6J, independent to the direction of change. A Mann-Whitney non parametric t test was then
performed to determine if the magnitude of change in persulfidation in the gluconeogenesis pathway was significantly higher than
that of the overall the dataset.
Persulfidation labeling and western blotting from frozen liver
80-120 mg of frozen liver samples were homogenized on ice using a 2 mL glass Dounce homogenizer (Kimble), in 500 ml buffer (7 M
urea, 100mMTris pH 7.5, 150mMNaCl, 1mMEDTA, 1%Triton X-100, 1%deoxycholic acid; supplementedwith cOmplete Protease
Inhibitor Cocktail (Roche)). Initial disruption of tissue was achieved with three passes, using the loose (Type A) pestle, and after 5 min
incubation on ice; complete homogenization was achievedwith 9 passes using the tight fit (Type B) pestle. Homogenates were centri-
fuged at 5000 rpm (2655 g) for 5min at 4C. Protein concentrations of supernatants were determined using theDCBCA protein assay
(Bio-Rad). Protein (6 mg) from each sample, was made up to 1 mL with phosphate buffered saline (pH 8.0). Freshly prepared EZ-link
Maleimide PEG Biotin EZ-linker (Thermo Fisher 21902BID), was added to samples to 100 mM, and incubated for 1 hour at room tem-
perature with gentle mixing. Excess maleimide linker was removed from samples by acetone precipitation (3 volumes) at20C for 1
h, followed by centrifugation at 12000 rpm (17390 g) for 10 min at 4C. Protein pellets were washed with ice-cold acetone and then
dissolved in 250 ml of 50mMTris pH 8.0, 100mMNaCl, 1 mMEDTA, 1%SDS. To each sample, 750 ml of RIPA buffer (100mMTris pH
7.5, 150mMNaCl, 1 mMEDTA, 1% Triton X-100, 1% deoxycholic acid) was then added. An aliquot (20 ml) was taken from each sam-
ple for estimation of total input protein for normalization (described below). The remainder of the samples were split into duplicates
and incubated with gentle mixing, overnight at 4C with 320 ml of pre-washed streptavidin agarose beads (Thermo Fisher 20347).
Beads were washed 10 times with 0.8 mL washing buffer (30 mM Tris pH 7.5, 600 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1%
SDS), followed by one wash with phosphate buffered saline (pH 7.4). Beads were then centrifuged for 1 min at 1000 rpm (106 g)
to dry. Elution of the duplicate samples for western blot analysis was performed by adding 300 ml of elution buffer (30 mM Tris pH
7.5, 150 mM NaCl). For each sample pair, one duplicate was eluted in buffer supplemented with 10 mM DTT and the other without
DTT. The beads were incubated with the elution buffer for 1 hour at RT; and centrifuged for 1 min at 1000 rpm (106 g) to collect the
eluate. Each eluted sample was concentrated to 20 ul using an Ultra-0.5 Centrifugal Filter Device, 10 K cut-off (Amicon), as per the
manufacturer’s instructions. Eluted samples, and input protein samples were loaded in their entirety onto SDS-PAGE gels and trans-
ferred overnight at 4Cbywestern blotting onto PVDFmembrane. Total protein from each lane on themembrane was estimated after
staining with REVERT total protein stain (LICOR) according to the manufacturer’s instructions. Briefly, following overnight transfer
and after rinsing the blot with water, the membranes were incubated with REVERT total protein stain for 5 min, and rinsed twice
with wash solution. Blots were then imaged in the 700 nm channel with an Odyssey imaging system (LICOR). Each lane was
measured for its total integrated fluorescence intensity to obtain an estimate of the total protein in each lane. Measurements from
no-DTT eluted sample lanes were subtracted from DTT eluted sample lanes. Similar fluorescence measurements of input total pro-
tein lanes were used to normalize the eluted samplemeasurements, and this was used as ameasure of relative protein-persulfidation
rate.
Mass spec analysis of liver protein
Sample preparation; Tst—/— and wild-type (C57BL/6J) mouse strains were fed either high-fat (58% fat) or normal (low fat) diet. Livers
from mice were removed following decapitation, and snap frozen in liquid nitrogen. Four biological replicates from the 4 conditions
were used to isolated proteins and performed protein quantitation using iTRAQ 8plex. Liver tissue was homogenized using 1 mL of
8 M urea with HEPES buffer pH 8.0. The protein concentration was determined using the Bio-Rad RC DC protein assay kit (Bio-Rad,
Hercules, CA, USA). One hundredmicro grams of protein fromeach of the sampleswere reducedwith THP (Tris(hydroxypropyl)phos-
phine), alkylated with MMTS (methyl methanethiosulfonate) in 500 mM triethylammonium bicarbonate (TEAB, pH 8.5), trypsin di-
gested and subsequently label with iTRAQ 8plex accordingly to the manufacturer’s instructions. Electrostatic Repulsion-Hydrophilic
Interaction Chromatography (ERLIC) Peptide fractionation; Peptide fractionation was performed using a pH gradient. Labeled pep-
tides were dissolved in 100 mL of buffer A (100mM formic acid, 25% acetonitrile, pH 3.0), followed by fractionation in a 2.63 200mm,
5 mm, 200 Å PolySulfethyl A column (Poly LC Inc., Columbia,MD), using anUltimate 3000UHPLC+ focused (Thermo-Fisher Scientific)
system, operating at a flow rate of 0.2 ml/min. Twenty minutes of isocratic buffer A were followed by a linear gradient from 0% to
100% buffer B (100 mM ammonium formate, 25% acetonitrile, pH 6.0) over 20 min and then a final linear gradient from 0% to
100% buffer C (600 mM ammonium acetate, 25% acetonitrile, pH 6.0) over 10 min. A total of 22 fractions (1-min intervals) were
collected. All fractions were lyophilized and stored at 20C. Nanoflow Liquid Chromatography Tandem Mass Spectrometry;
NanoLC MS/MS analysis was performed using an on-line system consisting of a nano-pump UltiMate 3000 UHPLC binary HPLC
system (Dionex, ThermoFisher) coupled with Q-Exactive mass spectrometer (ThermoFisher, San Jose, CA. iTRAQ-labeled peptides
were resuspended in 2%ACN, 0.1% formic acid (20 mL) and 6 mL injected into a pre-column 300 mm3 5mm (Acclaim PepMap, 5 mm
particle size). After loading, peptides were eluted to a capillary column 75 mm3 50 cm (Acclaim Pepmap, 3 mmparticle size). Peptides
were eluted into the MS, at a flow rate of 300 nL/min, using a 90 min gradient from 0% to 35%mobile phase B. Mobile phase A was
2.5% acetonitrile with 0.1% formic acid in H2O and mobile phase B was 90% acetonitrile with 0.025% trifluoroacetic acid and 0.1%
formic acid. The mass spectrometer was operated in data-dependent mode, with a single MS scan in the orbitrap (400-2000 m/z at
70 000 resolution at 200 m/z in profile mode); automatic gain control (AGC) was set to accumulate 4 3 105 ions, with a maximume9 Cell Reports 37, 109958, November 9, 2021
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mented using higher energy collision dissociation (HCD) at normalized collision energy of 38% with an isolation window of 0.7 m/z.
MS2 spectra were acquired with a fixed first m/z of 100. The intensity threshold for fragmentation was set to 50 000 and included
charge states 2+ to 7+. A dynamic exclusion of 60 s was applied with a mass tolerance of 10 ppm. Data Analysis; Raw files were
converted to MGF files and searched against the mouse UniProt database (81033 sequences, released on March 2014) using
MASCOT Version 2.4 (Matrix Science Ltd, UK). Search parameters were peptide mass tolerance of 10 ppm, and MS/MS tolerance
of 0.05 amu allowing 2missed cleavage. iTRAQ8plex (N-term) and iTRAQ8plex (K) were set as fixedmodification, and acetyl (Protein
N-term), Methylthio (C) andOxidation (M) were allowed as variable modification. Peptide assignments with ion score cut-off of 20 and
a significance threshold of r < 0.05 were exported to Excel for further analysis. Data are available from the ProteomeXchange with
identifier PXD028909.
GO and KEGG enrichment analysis of proteome data
The data generated from the initial mass spectrometric analysis of iTRAQ labeled peptides from the 16 liver samples was analyzed by
FIOS. A total of 16 samples were QC analyzed using the arrayQualityMetrics Bioconductor package to identify sub-standard and/or
outlier samples. No samples were identified as outliers. All samples passed themanual and automated quality control based on three
metrics (MAplot, Boxplot and Heatmap). The exploratory analysis using PCA showed that the samples clustered perfectly into four
groups based on the factor Group (representing four genotype-diet combinations). The first PC captures the main source of variation
in the dataset and is showing a separation of the samples based on diet, where high-fat diet and control diet samples separate. The
second PC shows a separation between genotypes (Tst KO and WT). The hierarchical clustering and PCA plot both show a clear
separation based on the iTRAQ labels. This is expected as the iTRAQ labels are confounded with the Groups. While the observed
separation of the samples into groups is most likely due to the underlying biological differences, any technical variations (potentially
introduced during the wet lab processing) could be masked. The log2 ratio data were subsequently normalized within arrays using
loess, followed by normalization between samples using the Gquantile method. A total of 4 single and/or multi-factor comparisons,
using statistical approaches, were performed. The contrast ‘‘Tst KO vs WT mice (High-fat diet)’’ was analyzed at a cut-off (unad-
justed) p value < 0.01. Due to the known bias in fold-changemagnitudes of the iTRAQ technology, no fold-change cut-off was applied
to the significant differentially abundant proteins. With this threshold 551 proteins were differentially abundant in at least one of the
comparisons. The contrast ‘‘High-fat diet vs Control diet (WT)’’ had the most DAPs (432) while the contrast ’’ Tst—/— versus 6J mice
(High-fat diet)’’ had the least DAPs (83). Noticeably, the TST protein showed the strongest downregulation for both of the contrasts
comparing Tst—/— to 6J mice, consistent with gene deficiency and the fold change compression effect of iTRAQ. The full dataset
(4,322 identified proteins) was filtered to remove proteins having less than two detected peptides (on average across all 16 samples);
leaving 1,654 proteins for downstream analysis. Exploratory analysis using principal component analysis (PCA) showed that the da-
taset separated into four distinct groups based on the genotype-diet combinations along the two first principal components (PCs).
These 1,654 proteins were used for enrichment analysis for GO terms and KEGG pathways. Individual proteins were considered of
interest if they were found significantly different (p < 0.01) between selected pairwise comparisons. The four comparisons were
Tst—/— normal diet versus C57BL/6J normal diet, C57BL/6J high fat diet versus C57BL/6J normal diet, Tst—/— high fat diet versus
Tst—/— normal diet, and Tst—/— high fat diet versus C57B/6J high fat diet. Normalizedmean abundance of proteins was expressed as
Log2 fold change ratios for each comparison.
Transcription factor enrichment analysis
43 upregulated proteins were selected for analysis of their promoter sequences (selected on basis of P value < 0.05; adjusted for
comparison of diet and genotype). 67 control proteins were selected from the proteome data on the basis of their equivalence of
abundance between C57BL/6J and Tst—/—. We used a QIAGEN hosted/SABiosciences mouse database of promoter located tran-
scription factor binding sites. 34 transcription factors were chosen to analyze, based on either their a-priori prevalence in the pro-
moter of Tst—/— upregulated proteins (present in the promoters of more than 50% of the upregulated proteins) or on their links to
either sulfide or nutrient metabolism. The proportion of genes containing a TFBS was calculated for the upregulated set (43) and
the control set (67). The ratio of upregulated to control was then calculated. The number of genes with and without the presence
of the TFBS were analyzed for establishing statistical difference (Upregulated versus Control), using a Fisher Exact test (p < 0.05).
NRF2 target identification and proteome analysis
NRF2 target genes of the mouse liver were compiled from the following reviews (Cuadrado et al., 2019; Tonelli et al., 2018; Rooney
et al., 2018; Walsh et al., 2014). 106 genes were identified as target genes (upregulated at mRNA or protein level following NRF2 acti-
vation). 47 of these target genes were represented in our liver proteome, and each protein was checked for relative expression be-
tween Tst—/— and 6J (on normal diet, threshold of p < 0.01). 10 of the 47 target genes were lower in abundance in the Tst—/—
proteome, 37 unchanged, with none upregulated. To analyze whether this was statistically significant, we compared this to the per-
centage of proteins upregulated, downregulated or unchanged in the proteome database. 5.86% of proteins were upregulated,
5.62% downregulated, and 88.6% unchanged in the full database (1654 proteins total). Expected (mean) numbers of proteins
from a hypothetical set of 47 proteins, predict rounded values of 3 upregulated, 3 downregulated and 42 unchanged. We used these
as a reference to the actual data for NRF2 target proteins; 0 upregulated, 10 downregulated and 37 unchanged. A Freeman-HaltonCell Reports 37, 109958, November 9, 2021 e10
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found (PA = 0.039, PB = 0.047).
Electron micrograph imaging
Liver tissue for transmission electron microscopy was prepared following immersion fixation in 0.1 M PB buffer (pH 7.4, EM-grade)
containing 4% paraformaldehyde and 2.5% glutaraldehyde. 1mm tissue blocks were post-fixed in 1% osmium tetroxide in 0.1 M PB
for 45 min before dehydration through an ascending series of ethanol solutions and propylene oxide. Tissue blocks were then
embedded in Durcupan before ultrathin sections (60/70 nm) were cut and collected on formvar-coated grids (Agar Scientific,
UK), stained with uranyl acetate and lead citrate in an LKB Ultrostainer and then quantitatively assessed in a Philips CM12 transmis-
sion electron microscope (TEM).
Seahorse respiratory analysis
Primary hepatocytes (C57BL/6J and Tst—/—mice) were seeded immediately following purification onto collagen coated V7 Seahorse
24-well cell culture microplates (Agilent Technologies), in 200 mL medium (DMEM, 5.5 mM glucose, 10% FCS, 7 mM glutamine, and
penicillin/streptomycin antibiotics), for culture in a 5% CO2 37
C incubator. Experiments were performed between 22-28 hours
following collection from mice. Optimization experiments determined the optimal seeding density, which was then standardized
at 10,000/well. Optimization for drugs and compounds used in Seahorse experiments were performed separately with hepatocytes
for each genotype and dietary regime (normal or 58% high fat). This established the doses of drugs for respiratory manipulation,
which were the same for both genotypes and diets; oligomycin (2 mM), FCCP (0.5 mM), and antimycin/rotenone (1 mM/0.2 mM). In
all experiments, overnight media from cells was replaced, after two washes (0.75 ml), with 525 mL of run media and incubated for
30 mins at 37C (without CO2), prior to entry into the Seahorse XFe24 Extracellular Flux Analyzer (Agilent). The analyzer was operated
using Wave software (Agilent), and all oxygen consumption rate (OCR) data was normalized to protein using the Sulforhodamine B
stain (described above). Data from each biological replicate was averaged from between 4-10 replicate wells, to produce a single
value at each measurement time for each biological replicate. Respiratory parameters were calculated as described below for
each biological replicate, and this data was used for statistical analysis of genotype effects.
Mitochondrial stress test (MST)
Run media for the MST was Seahorse assay media (Agilent), supplemented with 10 mM glucose, 2 mM sodium pyruvate, pH 7.35 ±
0.5 at 37C). Most measurements were made using 3 min mixing, 2 min wait, 3 min measure. Measurements following addition of
FCCP to hepatocytes from high fat fed mice were measured using 4 min mix, 2 min wait, 2 min measure. Three measurements
were taken basally, and three measurements taken after injection of each drug (in sequence; oligomycin for inhibiting ATP-linked
respiration, FCCP for eliciting maximal uncoupled respiration, antimycin/rotenone for inhibiting the respiratory electron chain). Res-
piratory parameters for each biological replicate were calculated from the mean normalized OCR as follows. Basal respiration was
calculated by subtracting the third OCR measurement following injection of antimycin/rotenone (12th measurement) from the third
basal OCR measurement (3rd measurement). ATP linked respiration was calculated by subtracting the third OCR measurement
following the injection of oligomycin (6th measurement) from the third basal OCR measurement (3rd measurement). Maximum
(uncoupled) respiration was calculated by subtracting the third OCR measurement after injection of antimycin/rotenone (12th mea-
surement) from the first measurement (peak OCR) following injection of FCCP (7th measurement). Proton leak respiration was
calculated by subtracting the third OCR measurement after injection of antimycin/rotenone (12th measurement) from the third mea-
surement following the injection of oligomycin (6th measurement). Non-respiratory OCR was taken from the third measurement after
the addition of antimycin/rotenone (12th measurement).
Octanoate rescue test
To investigate lipid respiratory metabolism, hepatocytes were prepared, seeded and cultured overnight as above. Run media for the
Octanoate rescue was Seahorse assay media (Agilent), supplemented with 5 mM glucose, 0.1 mM sodium pyruvate, 1 mM sodium
lactate, and 0.5 mM carnitine pH 7.35 ± 0.5 at 37C). All measurements were made using 3 min mixing, 2 min wait, 3 min measure.
After washing cells into runmedia, and 30min before entry into the analyzer, half of the wells from each genotype were incubated with
8 mM etomoxir (or DMSO vehicle) to block carnitine dependent import of long chain fatty acids into the mitochondria. Three basal
measurements were taken prior to injection of oligomycin, two measurements were taken prior to FCCP, two measurements
were taken prior to injection of sodium octanoate (250 mM), three measurements taken prior to antimycin/rotenone followed by
two final measurements. Standard respiratory parameters were calculated analogous to the above description for the standardmito-
chondrial stress test, except using the second measurement following injection of drug when only 2 measurements were taken. De-
pendency upon endogenous fatty acids for supporting uncoupled respiration (Etomoxir inhibited respiration) was calculated for each
biological replicate using the maximal respiration prior to the addition of octanoate. Maximal respiration was calculated as the 6th
measurement (peak FCCPOCR) – 12thmeasurement (lowest Antimycin/RotenoneOCR). Themeanmaximal respiration from the eto-
moxir treated wells was subtracted from the mean maximal respiration of the vehicle treated wells to calculate the Etomoxir inhibited
respiration (long chain fatty acid dependency) for that biological replicate. Octanoate stimulation of respiration (Octanoate stimulatede11 Cell Reports 37, 109958, November 9, 2021
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ment) from the third measurement after injection of octanoate (10th measurement).
Real time for mRNA analysis
RNA extraction, cDNA synthesis and real-time PCR were performed as described (Morton et al., 2011; Moreno-Navarrete et al.,
2013). Probes weremouseMpst, Mm00460389_m1, Tst, Mm00726109_m1;Gapdh (internal control), Mm99999915_g1; and Tbp (in-
ternal control), Mm0000446973_m1.
QUANTIFICATION AND STATISTICAL ANALYSIS
For analytes, bioenergetics, fluorescent probes, gene expression, and protein levels, generally group sizes of 6 were calculated to
allow detection of differences in these variable parameters to a threshold of 15% (there is sufficient power to detect smaller differ-
ences in certain parameters with this cohort size) with a power of at least 0.8. In some studies, limitations in animal numbers, or fewer
remaining samples from larger group sizes resulting from their use for multiple end-points, precluded the desired minimum of n = 6
per group. Protein or mRNA differences in validation studies with 2 parameters (e.g., diet with line or genotype) were analyzed using
2-way ANOVA for line and diet effects followed, where appropriate, by post hoc Tukey tests or Holm-Sidakmultiple comparison tests
using Sigmastat version 3.5 (Systat Software) or Prism (Graphpad Software). For simple 2 condition comparisons, t test was used.
For simple control versus treated (including different treatments or concentration response curves) data were analyzed by 1-way
ANOVA. For longitudinal measures (e.g., PTT, ITT, bodyweight gain) repeated-measures (RM) ANOVA was used and multiple com-
parisons determined. For all main in vivo studies, a blinding strategy was used where the operator (e.g., for injections of glucose, or
administration of drug) was blind to the genotype of the subject during the experiment. Similarly, for analysis of images (e.g., oil-red O
staining) the scorer was blind to genotype and the data coded, with the code broken by a second individual. Downstream analysis of
e.g., tissue mRNA and protein content was not generally blinded to allow appropriate data arrangement on e.g., representative west-
ern blots. For clamp studies, mean ± standard error of mean (sem) will be presented, statistical analysis will use t test to investigate
differences of genotype on each diet (2 independent experiments, normal diet, and high fat diet, are not compared directly to each
other). Statistical significance and the number (n) of subjects or samples for analysis are indicated in the figure legends.Cell Reports 37, 109958, November 9, 2021 e12
